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This dissertation focuses on developing analytical methods to study 
biomarkers in different pharmaceutical samples. Three different analytical 
methods were developed for microdialysis samples and antibody drug 
conjugates as anti-tumor drug. 
The first part of this dissertation is to develop a capillary 
electrophoresis with laser induced fluorescence (CE-LIF) method to 
monitor the change of amino acids in rat brain microdialysate as 
biomarkers of oxidative stress in epileptic seizures. Ornithine and citrulline 
was successfully separated and quantified. 3-Mercaptopropionic acid (3-
MPA) was administrated to rat brain hippocampus region as a convulsant 
to induce epileptic seizures to free-moving rats. An increase of citrulline 
and ornithine level was observed after the seizure, and this confirmed 
nitric oxide were produced in epileptic seizures. 
In the second project, a high-performance liquid chromatography 
with mass spectrometry (HPLC-MS) method is developed to 
simultaneously monitor the change of 13 eicosanoids as biomarkers in rat 
colon microdialysate to study the enzymatic pathways of inflammatory 
bowel disease. Moreover, cyclodextrin were added into microdialysis 





The last part is to utilize enzyme deconjugation and HPLC-UV-Vis 
to study the stability and compatibility of antibody drug conjugates (ADCs). 
Bromelain was utilized as an enzyme to fully cleave off the small molecule 
cytotoxic drug from the ADCs. This allows a direct analysis of the small 
molecule cytotoxic drug on the ADCs. The stability of antibody drug 
conjugates was studied with LC-UV-Vis after mixing with other conjugation 
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1 Introduction of Microdialysis 
1.1 Microdialysis  
Microdialysis is a commonly practiced in vivo sampling method that 
can be used to recover small molecules from or administer a drug to a 
target tissue. A 100-500 μm diameter probe containing a dialysis 
membrane is used to effectively recover analytes from the extracellular 
fluid (ECF) of tissue or deliver exogenous drugs to tissues of interest. This 
is accomplished by perfusing a liquid through a probe implanted into the 
tissue using a solution similar in composition and ionic strength to 
extracellular fluid. Sampling and delivery of substances in the tissue can 
both be accomplished due to the differential concentration gradient 
between the perfusate and the ECF, thus a diffusion-based sampling 
technique. (Figure 1.1) 
 Plasma concentrations are commonly used for 
pharmacokinetic/pharmacodynamic (PK/PD) studies in the drug 
development. Drug doses are usually determined on the basis of their PK 
behavior that is determined from plasma concentrations. This is based on 
the assumption that the tissue-to-plasma drug concentration is in 
equilibrium. This assumption is reasonable for those drugs that exert their 
effects in the bloodstream. However, since most drugs act in peripheral 




PK values can vary from person to person. There is nothing simple about 
the human body and the complexities associated with understanding and 
modeling different tissues and the effects of blood flow, protein binding, 
and pH. Other techniques have been developed to solve the oversimplified 
PK activity issue, for example, skin blister fluid, tissue biopsy or 
mathematical modeling. Another approach is to determine the 
concentration of the drug in the ECF most closely related to the site of 
concern to monitor real drug activity. Microdialysis is an effective sampling 
method that makes it possible to directly measure drugs in the ECF in a 
variety of tissues.1,2 Another advantage of microdialysis sampling for PK 
studies is that the ECF concentrations can be continuously monitored from 
a single animal. This greatly reduces the number of animals needed for a 
















Figure 1.1 A scheme of general microdialysis sampling mechanism. 
Perfusate similar with extracellular fluid composition is perfused through the 
probe. Small molecules in the tissue diffuse through the semipermeable 
membrane driven by concentration gradient. Molecules larger than the molecular 
















The concept of microdialysis was initially used by Kalant in 1958 to 
measure steroid concentration in the blood.3 Bito et al. used this dialysis 
based technique to sample amino acids in cerebrospinal fluid (CSF) from 
dogs in 1966.4 In 1974, Ungerstedt and Pycock developed the 
microdialysis technique as we know it today. They used a hollow fiber 
microdialysis probe to monitor amphetamine induced dopamine release in 
the rat brains.5 Now microdialysis has become a standard sampling 
technique that is widely used in neuroscience and pharmacological 
research. The U.S. Food and Drug Administration (FDA) has approved 
microdialysis catheter use for human brain studies.2  
The microdialysis sampling process is similar to that of a small 
blood vessel. It is accomplished by implanting a short hollow 
semipermeable dialysis fiber into the tissue of interest. Similar with the 
exchange of nutrients and waste products in a blood vessel, small 
molecules in the extracellular fluid diffuse through the probe into the 
perfusate and elute as dialysate. Conversely, small analytes in the 
perfusate can be delivered to the tissue in a manner analogous to nutrient 
delivery by blood vessels to tissues.  
The simplest probe design is the linear probe, which is produced by 
affixing a piece of dialysis membrane to two pieces of narrow bore tubing 
on each side as inlet and outlet. (Fig 1.1) Small molecules diffuse across 




and DNA, are excluded.2, 6-8 Another probe design, the concentric probe, 
can be implanted into the brain using a guide cannula.9,10 A flexible 
version of this concentric probe can be used to monitor compounds in the 
blood. Linear probes can be used to sample the ECF of many other soft 
tissues including colon,11 heart,12 and muscle.13 More details of the probe 
design are described in the next section. 
The perfusate used in microdialysis sampling is a physiologically 
compatible solution similar in composition and ionic strength to the ECF 
and is pumped through the probe slowly, generally with a flow rate of 0.1 
to 5.0 μl/min. Examples of perfusates include saline, Ringer’s solution, and 
artificial cerebrospinal fluid (aCSF).7  
Mass transport of compounds across the membrane is driven by 
the concentration gradient between the ECF and the perfusate. 
Theoretically, if the perfusate is perfectly matched to ECF, there should be 
no net fluid loss. The solute exchange direction depends on the 
concentration gradient orientation. When the concentration of a solute in 
ECF is higher than the concentration in perfusate, the solute diffuses into 
the probe. This process is called recovery. On the other hand, if the 
concentration in ECF is lower than that of perfusate, the solute diffuse into 
the tissue, making delivery possible.6  
1.2 Microdialysis Probe Design 




sampling. For example, the brain is a very heterogeneous tissue and 
generally requires site-specific probes to sample specific brain regions. On 
the other hand, other tissues, such as the colon, are more homogeneous, 
so site-specificity is not as critical as that of the brain. There are different 
probe designs developed for specific tissues; these include the concentric, 
linear, flexible and shunt probe.8,14 (Figure 1.2) 
1.2.1 Concentric Probe 
A concentric probe is commonly used for brain microdialysis 
sampling. It consists of two tubes—one placed inside the other. The 
semipermeable membrane is located at the end of the inner tube. The 
probe is approximately 15 mm long, and the semipermeable membrane is 
between 1-4 mm. In the brain sampling experiment, a pin-style cannula is 
first implanted into the brain to guide the microdialysis probe into the 









Figure 1.2 Microdialysis probe design: (A) concentric cannula (B) linear 






 1.1.  Microdialysis Probes 
 Several different types of probes are available for microdialysis sampling 
(Figure  2 ). Probes have been designed specifi cally for brain, blood, tissue, and 
bile sampling. Special probes have also been developed for bioreactor and 
dissolution monitoring. Many different membrane materials are used to make 
microdialysis probes, including cellulose acetate, polyacrylanitrile (PAN) 
polycarbonate – polyether (PCE), polyether sulfone (PES), and cuprophan 
(CUP). Selection of the appropriate membrane for the application of interest 
depends on the target analyte and sample matrix. 
 Concentric Cannula  The concentric cannula is the most commonly employed 
design for neurochemical studies (Figure  2 A). These probes are composed of 
stainless steel and are implanted into the specifi c region of interest using a 
guide cannula. A typical probe used for rat brain studies is approximately 
 Figure 2  Probes used for microdialysis sampling: (A) concentric cannula design; 
(B) linear probe; (C) fl exible probe (from CMA product catalog); (D) shunt probe. 
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1.2.2 Linear Probe 
A linear probe is commonly used in tissues where the spatial 
resolution is not critical, such as the liver, heart and colon. The 
semipermeable membrane has a length of 4–10 mm and a diameter of 
100-500 μm, connected by two pieces of flexible tubing.  
The probe is commonly guided through the tissue by a needle 
acting as the guide cannula. Since the spatial resolution is not critical here, 
the membrane length can be larger than that used in concentric probe 
designs. Therefore, the recovery achieved with a linear probe can be 
better than the concentric probe. It is also widely used for in vitro 
experiments, such as drug dissolution studies. (Figure 1.2B) 
1.2.3 Other Probe Designs 
Telting-Diaz et al.15 designed a flexible probe to sample blood in 
freely moving rats. This probe had a similar design with that of a cannula 
style brain probe. The only difference is that, instead of the rigid tubing 
required by brain experiments, flexible probes use capillary tubing that can 
bend in the blood vessel when the animal moves. Scott and Lunte 
designed the shunt probe to sample moving fluids.16 The primary 
application of shunt probe is bile analysis. A piece of plastic tubing is 
implanted in the bile duct and a linear microdialysis probe is placed inside 
of the tubing. Another interesting application of the shunt probe is to desalt 




1.3 Microdialysis Recovery 
1.3.1 Extraction Efficiency and Relative Recovery 
Since microdialysis sampling is a dynamic sampling technique, the 
perfusate is continuously pumped through the probe and, even at low flow 
rates, concentration equilibrium is not usually established between inside 
and outside of the membrane. We assume the microdialysis is under 
steady state when the concentration equilibrium is reached. The 
concentration of the analyte in the dialysate is usually a fraction of that 
presents in the external tissue. The term extraction efficiency (EE) is 
introduced here to describe this fraction. Extraction efficiency is defined by 
the following equation: 
EE = !!!!!
!!!!!
                                    (Equation 1.1) 
where Cp is the concentration in the perfusate, Cd is the concentration in 
the dialysate and Cs is the concentration in the ECF. In an in vivo 
microdialysis recovery study, Cp is usually zero. In this particular case, the 
extraction efficiency is also called relative recovery (RR)2.7: 
RR = !!
!!
                                       (Equation 1.2) 
1.3.2 Improvement of Recovery  
Relative recovery is also defined as: 
RR = 1 − exp  [− !
!! !!!!!!!!




where Qd is flow rate of perfusate, Rd is the mass transport resistance of 
dialysate, Rm is the mass transport resistance of the membrane, and Re is 
the mass transport resistance of extracellular space. The membrane 
refers to the semipermeable membrane of the microdialysis probe. The 
dialysate is the solution carrying small molecules out of the probe. 
Therefore, microdialysis recovery can be improved by changing these 
parameters as discussed below.14,18  
1.3.2.1 Flow Rate 
From the Equation 1.3, it can be seen how decreasing the flow rate 
can improve analyte recovery. However, in real practice, this is not 
suggested because it will reduce the dialysate sample volume per unit 
time. For the in vivo rat experiments in this dissertation, the sampling time 
interval was 10-15 min and the common flow rate was 1 μL/min, so the 
sample volume collected was 10-15 μL. For example, if we reduce the 
flow rate to 0.5 μL/min, the sample volume would be 5-7.5 μL. In our in 
vivo studies, the samples were usually divided for analysis by at least 
three different analytical systems to monitor the change of different 
biomarkers. In order to accurately pipet and inject the samples, the sample 
volume needed for each analytical system had to be larger than 2 μL. 
Therefore, lower sample volumes (5-7.5 μL) can result in bad 
reproducibility or accuracy. To achieve both larger sample volumes and 




samples for longer time; however, this will compromise the temporal 
resolution in PK studies. 
1.3.2.2 Diffusion 
According to the Stokes–Einstein equation, the diffusion coefficient 
can be expressed as: 
D = !!!
!"#$
                              (Equation 1.4) 
where kb is the Boltzmann constant, T is temperature, η is the viscosity of 
the medium, and σ is the particle radius. Therefore, temperature and 
molecule size will influence diffusion of the analyte and influence recovery. 
Rd is related to the diffusion of the analytes in the dialysate, which 
includes dialysate composition. Re takes into the consideration of the 
extracellular environment of tissues, including tissue tortuosity and other 
metabolic processes such as enzyme digestion.19 Re also can be affected 
by the tissue damage during probe implantation.14 
1.3.2.3 Membrane Material 
Rm is related to the membrane material. Commonly used membrane 
materials include polyacrylonitrile (PAN) polyethersulfone (PES), 
polyarylethersulfone (PAES), cuprophan (CUP), and cellulose acetate.14 
The hydrophobicity or charge of the membrane influences the recovery. 
Different molecular weight cutoffs of different membrane materials also 




semipermeable membranes used in microdialysis studies range from 20 to 
100 kDa. Moreover, physical parameters, such as membrane length and 
probe geometry, also influence the recovery of different compounds.20  
1.3.2.4 Affinity Trapping Reagents 
Affinity trapping reagents have been added to the perfusate to 
improve analyte recovery. They can attract the analytes of interest to the 
microdialysis probe through a concentration gradient and bind with them 
after diffusing into the probe. This decreases the concentration of target 
analytes near the membrane to almost zero. According to Fick’s law, the 
diffusion of a molecule is dependent on the concentration gradient across 
the probe.18 Affinity reagents will increase the concentration gradient and 
improve relative recovery. (Figure 1.3)  
Stenken’s group has performed extensive research on improving 
recovery by adding cyclodextrin and antibodies to the perfusate.21 The 
cone shaped cyclodextrin molecule can react with low solubility analytes to 
form an inclusion complex and improve the recovery.22 In another 
application, Stenken’s group improved cytokines recovery by adding 












Figure 1.3 A scheme of improving microdialysis recovery by adding 
affinity-based trapping agents in microdialysis perfusate. The affinity agents trap 
analytes diffused in the probe. The concentration gradient is increased and the 











1.4 Calibration Methods 
Under normal flow rate (1 μL/min) conditions, concentration 
equilibrium between the ECF and dialysate is not always achieved, 
especially in more tortuous tissues, such as brain, liver or muscle; 
therefore, the recovery is usually not 100%. When the exact ECF 
concentrations are needed, the microdialysis probe needs to be calibrated 
first.  
1.4.1 No Net Flux Method 
The no net flux (NNF) method is used to determine steady state 
concentrations of analytes in the tissue. To perform NNF, several different 
concentrations of a known analyte are added into perfusate. The 
microdialysis probe is implanted into target tissue, and a series of 
perfusates with known concentrations are perfused through the probe, and 
the dialysate is collected. When choosing the concentrations of the known 
analyte to use in the experiment, the concentration range should include 
the expected ECF concentration. Figure 1.4 is an example of the NNF 
plot. Cp stands for the known concentration in the perfusate, Cd refers to 
the concentration in the collected dialysate. A graph of Cp-Cd vs. Cp is 
plotted. When Cp-Cd equals to zero, there is no net flux, and Cp is the 











Figure 1.4 An example of a no net flux plot. The x-intercept is the no net 





























No Net Flux Plot




1.4.2 Dynamic No Net Flux Method 
In more complicated cases, when drugs are administrated or 
endogenous compounds concentrations change over time, the steady-
state no net flux method is not applicable. The dynamic no net flux method 
requires groups of animals instead of a single animal; so the concentration 
change over time can be monitored. In the dynamic no net flux method, 
different concentrations of a known analyte are perfused into different 
animals and Cd at each time point is measured while the corresponding no 
net flux graph is plotted so the extracellular concentration change can be 
obtained.26  
1.4.3 Retrodialysis 
Retrodialysis, also called reverse dialysis, is an easier method to 
measure the concentration of exogenous analytes. It is based on the 
assumption that the diffusion of a compound is the same for both 
directions across the semipermeable membrane. A known concentration 
of a calibrator that has similar diffusion and metabolism properties as the 
target exogenous analyte is added into the perfusate. Another assumption 
is that the concentration of the target exogenous analyte in the 
extracellular fluid is zero. 
Recovery   % = 100 − (100× !!
!!
)              (Equation 1.5) 




exogenous analytes that are not present in the extracellular fluid such as 
administered drugs, and it cannot be used to monitor concentration and 
recovery changes over time.2,14,27  
1.5 Advantages and Disadvantages of Microdialysis 
1.5.1 Advantages 
The microdialysis sampling process is driven by a concentration 
gradient; therefore, there is no net fluid loss across the membrane. It 
allows continuous sampling from the same animal, so the animal can 
serve as its own control. This can greatly reduce the number of animals 
used. Long-term studies in awake animals can also be achieved by 
microdialysis.  
The semipermeable membrane on the microdialysis probe excludes 
large molecules such as proteins. Therefore, the microdialysis sample can 
normally be injected directly into the analytical system without sample 
preparation.  Biochemical degradation of analytes is also inhibited 
because enzymes are excluded by the dialysis membrane. 
Microdialysis is a site-specific sampling technique.  It samples the 
drug or endogenous species at the site of action, making it a very powerful 
tool for PK/PD studies. It also can locally deliver the exogenous drug to 
the site of interest, reducing systemic adverse events.7,8,18  
1.5.2 Disadvantages 




surgery and will result in local tissue damage. Studies have shown that 
biomarkers such as thromboxane B2, K+, and lymphocytes are elevated,28 
and inflammation responses are observed following probe 
implantation.2,18,29  In addition, microdialysis samples are usually small 
volumes (1-20μL) and high salt concentration; this can make analytical 
method development challenging. Analytical considerations of 
microdialysis sampling are discussed in the following section.2 
1.6 Analytical Methods for Microdialysis Sampling 
1.6.1 Liquid Chromatography 
1.6.1.1 LC theory 
Liquid chromatography (LC) is one of the most commonly used 
separation methods. The separation is based on the interaction of 
analytes between a mobile phase and stationary phase. There are several 
types of chromatography such as normal phase liquid chromatography, 
reverse phase, size exclusion chromatography, ion pairing 
chromatography. For microdialysis samples, reverse phase LC is more 
commonly used, since the dialysate are aqueous-based solutions. 
Isocratic separations is a simple method to begin with, where only 
one constant solvent composition is used as the mobile phase. However, if 
the polarity difference between different analytes is too large, the analysis 
time can be very long. Gradient elution, that changes the mobile phase 




There are several factors that are used to describe LC performance. 




                            (Equation 1.6) 
where tan is the retention time of the analyte, t0 is the void volume of the 
column that is defined as the time required for an unretained analyte to 
elute from the column.  
The separation of two analytes, A and B, is described by the 
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                         (Equation 1.8) 
where wA and wB are the peak widths, tA and tB are the retention time of A 
and B. 
The column efficiency is described by plate height (H). The column 
efficiency per unit length is described by plate number (N) 
N = 16( !!
!!
)! = 5.54( !!
!!.!
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1.6.1.2 LC in Microdialysis 
The limitation of LC for the analysis of microdialysis samples comes 
from the low sample volumes obtained. A typical flow rate used in 
microdialysis is ~1 μL/min, resulting in a sample volume at each time point 
of 5 to 10 μL and a  temporal resolution between 5 and 10 min. Increasing 
the flow rate will increase the sample volume collected; however, it will 
decrease the recovery, which produces another analytical challenge due 
to the limits of detection. Another way to solve the sample volume issue is 
to compromise the temporal resolution, though this is not ideal.14 
In order to minimize zone dispersion and improve the limits of 
detection, while maintaining temporal resolution, microbore columns and 
capillary liquid chromatography (cLC) have been used. The common inner 
diameters of microbore columns range from 0.3 to 1.0 mm. The smaller 
column diameter leads to less peak dispersion, so the limit of detection 
can be improved with the same detector. The temporal resolution of 
microbore LC can be 3-5 min with 3-5 μL injection.30  
In recent years, cLC has become a good solution for the LOD issue. 
The inner diameter of cLC is 25 to 150 μm, which allows for LOD as low 




fluorescence detection.31 The off-line temporal resolution achieved with 
this method was as fast as 10 seconds.30 However, the smaller diameter 
column requires a slower flow rate, so the separation times are relatively 
long, such as ~30 min, so cLC is not a good option for on-line 
microdialysis analysis.14,30,32  
1.6.2 Capillary Electrophoresis 
1.6.2.1 CE Theory 
Capillary electrophoresis (CE) is a more microdialysis compatible 
separation method than LC; since it only requires pL to nL injection 
volumes and can perform faster separations. In capillary electrophoresis, 
the analytes are separated based on difference in electrophoretic mobility. 
A fused silica capillary is filled with background electrolytes (BGE), and 
high voltage is applied across the capillary. In conventional capillary zone 
electrophoresis, the migration of analytes is determined by two factors, 
electroosmotic flow (EOF) and size to charge ratio (electrophoretic 
mobility).  
EOF is the result of an electrical double layer, and serves as bulk 
flow in CE separation. Typically, the BGE has a pH > 3 so that the silanol 
groups at the inner wall of the fused silica capillary are ionized. The 
negatively charged capillary wall attracts cations in BGE and builds an 
electrical double layer, referred to as an inner Helmholtz layer at the 




migrates towards the outlet (normal polarity) and creates EOF. The 
magnitude of EOF (veof) is defined as:  
v!"# = εζE/η                             (Equation 1.12) 
where ε is the dielectric constant of the buffer, ζ is zeta potential of the 
electrical double layer, E is electric field and η is the viscosity of BGE. 
The analyte velocity due to electrical field v is described as 
v!" = µμΕ =
!!
!
                  (Equation 1.13) 
where V is the applied voltage, L is total capillary length, and μ is the 
electrophoretic mobility that is determined as: 
µμ = !
!"#!
                               (Equation 1.14) 
where q is the charge of analytes, R is the hydrodynamic radius of 
analytes. Therefore, the actual electrophoresis velocity is the combination 
of EOF and electrophoretic velocity of the analytes.  
v!"" = v!" + v!"#                  (Equation 1.15) 
Stacking methods are used in capillary electrophoresis to improve 
the LOD. Stacking is a sample preconcentration method based on the 
different electrophoretic mobility of ions on the boundary of different 
solution plugs in the capillary. The stacking is based on different electric 
field strength. According to Ohm’s Law, the solution with lower conductivity 




solution. When the ions migrate to the boundary of higher conductivity 
solution, their velocities are decreased leading to stacking.33  
1.6.2.2 CE in Microdialysis 
Capillary electrophoresis (CE) is a common separation method for 
the analysis of microdialysis samples. The injection volume is usually in 
the nano liter range, which allows multiple injections of the same sample. 
The sample can also be split for analysis using different analytical 
systems. The separation efficiency of CE is better than LC. The theoretical 
plate number from CE separation can be as high as 300,000 to 500,000.34 
Moreover, microchip CE (MCE) is gaining favor since it can achieve even 
faster separation, and smaller volume for on-animal sensing. 
One disadvantage of CE and MCE is that the perfusate, such as 
Ringer’s solution, saline, or aCSF, normally has a much higher salt 
concentration than BGE. This leads to a conductivity difference between 
the sample plug and BGE. When a constant voltage is applied across the 
capillary, destacking will happen due to the electrical field drop across the 
sample/BGE boundary. Destacking will cause band broadening and result 
in a loss of sensitivity and resolution. Joule heating caused from solution 
resistance is another reason for band broadening. The separation voltage 





1.6.3 Mass Spectrometry 
1.6.3.1 Mass Spectrometry Theory 
Mass spectrometry (MS) is a standard detector for pharmacokinetic 
studies, since in addition to good sensitivity; the MS/MS mode can also be 
regarded as secondary separation step. MS can be coupled with either LC 
or CE, although LC is more commonly used. MS detection and 
identification analysis is based on ions mass to charge ratio (m/z). 
The first step in MS is ionization, analytes are converted into 
gaseous phase ions in the ionization source. The most commonly used 
ionization source for the analysis of microdialysis sample is electrospray 
(ESI). ESI is a soft ionization method with very high sensitivity, and it can 
be easily connected to a liquid chromatography or capillary 
electrophoresis.  
The positive ionization mode is used as an example to explain the 
electrospray ionization mechanism here. The LC eluent continuously flows 
through a capillary tube. A high positive voltage (3–6 kV) is applied across 
the capillary and counter-electrodes, and an inert gas coaxially flows along 
the capillary and liquid. An excess positive charge accumulates on the 
liquid surface and charged droplets are formed. As the inert gas sprays, 
the liquid evaporates and droplets shrink, resulting in an electrical field 
increase. When the electrical field force gets larger than surface tension 




droplets on the tip, producing an electrospray.35,26 
The ionized analytes then go into a high vacuum mass analyzer, 
which detects the m/z. Common mass analyzers include ion trap, triple 
quadrapole and time-of-flight (TOF). An ion trap is used as an example to 
illustrate how to detect m/z. A traditional 3D ion trap consists of three 
electrodes: one top ellipsoid electrode, one bottom ellipsoid electrode and 
one circular electrode in the middle. These three electrodes form a box in 
the middle. The ions are trapped in the middle box and are expelled based 
on their m/z. The linear ion trap, also know as a 2D ion trap, has a 10 fold 
higher ion trapping capacity. (Figure 1.5) It replaces the middle circular 
electrode with quadrupoles. In the linear ion trap, the mass analyzer is 
able to not only analyze the parent ions, but it can also conduct tandem 
MS analysis. In tandem MS, inert gas molecules are introduced into the 
high vacuum chamber and collide with the parent ions. This causes parent 
ions to break up into different fragments; hence, tandem MS can greatly 
improve selectivity and sensitivity, as well as provide structural information 
of the analytes.37 
1.6.3.2 MS Analysis of Microdialysis Samples 
One issue with MS analysis of microdialysis samples comes from 
the high salt concentrations of the perfusate. With ESI ionization, the high 
salt can result in ion suppression that will reduce ionization efficiency. 




clog the capillary. To solve this problem, a divert valve can be used that 
allows the first several minutes of eluent flow to directly go into the waste 
reservoir instead of LC-MS system. Salts usually exhibits low retention on  
reverse phase columns and the valve reduces the amount of salt that goes 
into the ESI source. Sample pre-treatment, such as solid phase extraction 
(SPE), can also be a solution. However, for very small volume samples, 











Figure 1.5 An illustration of linear ion trap mass spectrometry. The top 



















In this dissertation, three different analytical methods were   
developed and used to study biomarkers in microdialysis samples and the 
stability of antibody drug conjugates. Chapter two describes the 
development of a CE-LIF method to study changes in amino acids in rat 
brain microdialysates during epileptic seizures. Chapter three and four 
describe the development of an LC-MS method to detect eicosanoids in 
rat colon microdialysate samples to study inflammatory bowel disease. 
Chapter five describes the development of an enzymatic digestion and LC-
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2 A CE-LIF Method Development for the 
Determination of Amino Acids in Rat Brain 
Microdialysate to Study Epileptic Seizure  
2.1 Introduction 
2.1.1 Epileptic Seizures 
Epilepsy is one of the most common neurological disorders in the 
world. Epileptic seizures are caused by an abnormal neuronal imbalance 
in the brain. The brain disorder that generates multiple epileptic seizures is 
defined as epilepsy. It affects 3 million people in the United States and 70 
million people worldwide.1 Nearly 40 different anti-seizure drugs were 
developed between the year of 1850 and 2010, however, 32% of patients 
remain incurable.2,3 There are many causes of epilepsy, including trauma, 
tumors, genetic, however, the causes of over 50% cases of epilepsy are 
still unclear.   
2.1.2 Seizure and Oxidative Stress 
Seizure activity increases intracellular calcium concentrations and 
induces the production of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). This leads to oxidative stress, which is an 
important secondary effect of seizure activity. Common ROSs and RNSs 
include free radicals, such as hydroxyl (•OH), superoxide (O2•-) and nitric 




peroxides. Low concentrations of ROS and RNS are beneficial in 
biological processes, however, when endogenous antioxidants are unable 
to scavenge excessive amounts of ROS and RNS, oxidative stress 
happens.4 Epilepsy induced oxidative stress can lead to neurotoxicity and 
affect many other biological pathways. ROS and RNS can attack 
nucleotides, lipids, and proteins causing irreversible cellular damage and 
cell death. The central nervous system (CNS) is particularly vulnerable to 
the detrimental effects of ROS and RNS because it consumes a high 
amount of oxygen and has weaker antioxidant enzymes.5 Oxidative stress 
has been proposed to be a secondary effect and a cause of epilepsy, as 
well as other neurodegenerative disease, including Alzheimer’s disease 
and Parkinson’s disease.6  
2.1.3 Nitric Oxide 
This chapter focuses on one particular RNS, nitric oxide. NO is an 
abundant molecule in the brain and exhibits important physiological effects 
in vascular, immune and central and peripheral nervous systems. 
However, it reacts with other free radicals; for example, superoxide (O2−•), 
to produce peroxynitrite (ONOO-).7 Peroxynitrite is a more reactive oxidant 
than NO and it reacts with various biomolecules and eventually cause cell 
death.8 Both nitric oxide and peroxynitrite are unstable under physiological 




few seconds.8,9 Therefore, to monitor the production of NO, alternative 
stable biomarkers are necessary. 
Nitric oxide is produced through the nitric oxide synthase (NOS) 
pathway. There are three common types of NOS in the brain, including 
neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS 
(iNOS).7 nNOS and eNOS are Ca2+ dependent, and constitutively express 
low amount of NO in the cells10, while iNOS is Ca2+ independent and 
express high amount of NO after being induced.  
2.1.4 NO Production and Arginine Cycle 
NO is one of the products from arginine cycle (Figure 2.1). On the 
left side of the arginine cycle, NOS catalyzes the production of NO and L-
citrulline from L-arginine and with the present of NADPH and O2.11,12 NO is 
degraded into nitrate and nitrite within a few seconds and hard to be 
directly detected, so citrulline is chosen as a stable biomarker of NOS 
pathway. On the right side, arginine is also metabolized to L-ornithine and 
urea via the arginase pathway. These two pathways might compete each 
other.13,14 Ornithine is chosen as a biomarker of arginase pathway. In this 
chapter, the purpose was to develop a method that can be used monitor 
the production of nitric oxide in vivo. This will then be used to monitor the 
mechanism, damage, and treatment of oxidative stress in epileptic 
seizure. Therefore, a method that simultaneously detects citrulline and 















Figure 2.1 Arginine goes through NOS and arginase pathways 
simultaneously. Arginine is converted into citrulline and nitric oxide through NOS 















2.1.5 Analytical Methods 
The in vivo sampling technique used in these studies was 
microdialysis. As introduced in Chapter 1, microdialysis is a powerful in 
vivo sampling technique. It is able to sample from awake free-moving 
animals with good temporal resolution, thus it greatly reduce the number 
of animals utilized. The common microdialysis flow rate is 0.1-5 μL/min, 
and lower flow rates are preferred to achieve higher recovery. If one 
assumes a constant flow rate, smaller microdialysate volumes must be 
collected and analyzed to achieve better temporal resolution. In most 
cases the volume collected is typically 1-20 μL.15,16 The small sample 
volumes characteristic of microdialysis sampling makes capillary 
electrophoresis (CE) an ideal method for the analysis of these samples. 
The injection volume of CE is usually in nanoliter range as compared to 
several microliters for liquid chromatography. Therefore, we utilized CE as 
the separation method in this project. Moreover, in order to enhance the 
separation, (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD) was added to the 
background electrolyte in these studies, because cyclodextrins can form 
inclusion complexes with small molecules. 
Laser induced fluorescence (LIF) was employed as a detection 
method due to its high sensitivity and low detection limits. Since neither 
citrulline nor ornithine is natively fluorescent, pre-column derivatization 




2,1,3-benzoxadiazole (DBD-F) was chosen as the derivatization reagent 
here. DBD-F reacts with both primary and secondary amines and the 
corresponding derivatives exhibit fluorescence at excitation and emission 
wavelengths of 450 and 490 nm, respectively.17-19  
2.2 Experimental 
2.2.1 Chemicals and Reagents 
L-Citrulline (Cit), L-ornithine monohydrochloride (Orn), lithium 
tetraborate (LTB), (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD), 3-
mercaptopropinoic acid (3-MPA), and the internal standard 6-
aminocaproic acid (6-ACA) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Methanol, hydrochloric acid (HCl), sodium hydroxide (NaOH), 
glacial acetic acid (HAc), sodium acetate trihydrate (NaAc·3H2O), 
acetonitrile (MeCN), calcium chloride dihydrate (CaCl2·2H2O), magnesium 
chloride (MgCl2), potassium chloride (KCl), and sodium chloride (NaCl) 
were purchased from Fisher (Fair Lawn, NJ, USA). The derivatization 
reagent 4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole 
(DBD-F) were purchased from TCI America (Portland, OR, USA). Ethanol 
was purchased from Decon Labs, Inc (King of Prussia, PA, USA). 
Ultrapure water was prepared with a Milli-Q system (Millipore, Bedford, 
MA, USA) 
2.2.2 Solutions Preparation 




mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2 and 1.0 mM MgCl2. Amino acids 
standard stock solutions and the internal standard stock solution were 
prepared in 0.1 M perchloric acid and stored at 4 ℃ and diluted with 
Ringer’s solution prior to use. A 40 mM DBD-F solution was prepared by 
dissolving the solid in 1 mL MeCN and stored at 4 ℃. Optimization of the 
separation conditions were carried out using 10 μM standard solutions. 
2.2.3 Derivatization Procedure 
The derivatization reagent DBD-F reacts with primary and 
secondary amines groups of the amino acids and internal standard. The 
derivatization reaction is shown in Figure 2.2. For derivatization of the 
samples and standard 5 μL 40 mM DBD-F in MeCN was mixed with 5 µL 
amino acids standards/microdialysate sample and 2 μL 80 mM LTB. The 
reaction was allowed to proceed at 60 ℃ in dark for 90 minutes. The 









Figure 2.2 The DBD-F derivatization reaction. The reaction conditions 
consisted of 5 μL 40 mM DBD-F in MeCN mixed with 5 μL amino acids 








2.2.4 CE-LIF System 
A laboratory-built CE separation system was used in these studies. 
The fused-silica capillary was purchased from Polymicro Technology 
(Phoenix, AZ, USA). The internal diameter was 50 μm, the total length 
was 70 cm and the effective length was 55 cm. The capillary was 
conditioned with methanol for 5 min, 1 M HCl for 3 min, ultrapure water for 
3 min, 1 M NaOH for 20 min, millipore water for 3 min, and background 
electrolyte (BGE) for 20 min at 15 psi every day prior to performing 
analyses. Between each run, the capillary was flushed with 1 M NaOH for 
3 min, millipore water for 3 min and BGE for 3 min. An external ZETALIF 
detector from Picometrics (Toulouse, France) coupled with a laser (444.6 
nm) from CrystaLaser (Reno, NV, USA) was used. A Spellman CZE 
1000R high voltage power supply was used and data was acquired using 
a  Chrom&Spec Chromatography Data System (version 1.52y). 
2.2.5 CE Separation Conditions 
To separate the NO metabolites, a BGE consisting of 20 mM LTB, 
20 mM HP-β-CD, and 25% ethanol was employed. Prior to the separation, 
6 μL derivatized sample was mixed with 2 μL buffer, which consisted of 
135 mM HAc, 15 mM NaAc and 25% MeCN to obtain better resolution. 
This formed a stacking environment that reduced band broadening and 
improved the resolution. The sample was introduced by hydrodynamic 





2.2.6 Animal Procedures 
All animal experiments were performed in accordance with the local 
Institutional Animal Care and Use Committee. CMA 12 Elite 4 mm brain 
probes with a 20 kDa cutoff were purchased from CMA Microdialysis 
(North Chelmsford, MA, USA).  
Male Wistar rats (Charles River) weighing from 250-450 g were 
used for these studies. Aseptic techniques were utilized to minimize 
contamination and infections. The rats were initially anesthetized in an 
isoflurane chamber to effect, followed by intraperitoneal injection of an 
anesthetic cocktail: ketamine (67.5 mg/kg), xylazine (3.4 mg/kg), 
acepromazine (0.67 mg/kg). The rat body temperature was regulated at 37 
ºC by PhysioSuite temperature probe and heating pad (Kent Scientific 
Cooperation, Torrington, Connecticut, USA). The rat was shaved once it 
was fully under anesthesia. The brain cannula incision coordinates were 
determined by placing the rat in a stereotaxic apparatus. The skull was 
exposed and bregma line was identified. The CMA 12 microdialysis guide 
cannula (CMA, N. Chelmsford, MA) was implanted into the rat’s 
hippocampus CA3 region (-5.6 A/P, +4.8 L/M, and -5.0 D/V, relative to the 
bregma line).  
After surgery, the rat was placed into a Culex with Raturn System 




were provided. The microdialysis probe was inserted through the guide 
cannula into rat brain after it was put in the Raturn. The rat was allowed to 
recover from anesthetic immediately following surgery.  
2.2.7 Microdialysis Sample Collection 
Microdialysis sample collection was started 24 hours after recovery 
from the surgery. Perfusate with and without added convulsant were 
perfused through the probe using a BASi syringe pump (Bioanalytical 
Systems Inc., West Lafayette, IN, USA). The convulsant used to induce 
the seizures was 10 mM 3-mercaptopropinoic acid (3-MPA) dissolved in 
Ringer’s solution. Microdialysis samples were collected over 10 min 
intervals using a HoneyComb fraction collector (Bioanalytical Systems 
Inc., West Lafayette, IN, USA). Basal samples were collected for 2 hours 
by perfusing Ringer’s solution at a flow rate of 1.0 μL/min. Then, 10 mM 3-
MPA in Ringer’s solution was perfused through the probe for 50 minutes at 
1.0 μL/min flow rate. Following 3-MPA administration, the perfusate was 
changed back to Ringer’s solution. Sample collection was then continued 
for another 230 minutes. The control experiments followed the exact same 
procedures except that Ringer’s solution was perfused instead of 3-MPA 
during the 50 min dosing period. All microdialysis samples were stored at -




2.3 Method Development 
2.3.1 Internal Standard 
In order to improve the accuracy and reproducibility of the CE-LIF 
method, 6-aminocaproic acid (6-ACA), a derivative of lysine, was used as 
an internal standard. (Figure 2.3)  6-aminocaproic acid can be derivatized 
and separated from the other amino acids with the DBD-F derivatization 
method and has similar fluorescence properties to that of citrulline and 
ornithine. With 6-ACA, the reproducibility of the method was improved as 
shown in Table 2.1. The peak area %RSD of citrulline was improved from 







































2.3.2 Optimization of Separation Conditions  
The separation conditions were optimized to obtain the best 
resolution between adjacent peaks including ornithine and the internal 
standard, the internal standard and citrulline, citrulline and the DBD-F 
byproduct, and other peaks in the brain microdialysate sample. 20 μM 
lithium tetraborate (LTB) was used to provide steady electroosmotic flow 
(EOF). The lithium ion has larger hydrated radii compared to sodium ion. 
When anions are the same, lithium has lower electrokinetic mobility and 
provided more stable and slower EOF. Micellar electrokinetic 
chromatography (MEKC) was also evaluated by adding lithium dodecyl 
sulfate (LDS); however, it was not able to separate the complicated 
microdialysis samples.  
In order to improve resolution, (2-hydroxypropyl)-β-cyclodextrin 
(HP-β-CD) was added to the background electrolyte. HP-β-CD can form 
inclusion complexes with analytes through hydrogen bonding. The 
electrophoretic migration velocities of different analytes changed due to 
the different interaction with HP-β-CD.20 The resolution between the 
internal standard and citrulline peak, the two least resolved peaks in the 
electropherogram, was greatly improved with high HP-β-CD concentration 
as shown in Figure 2.4 (A). When the concentration of HP-β-CD was 
higher than 20 μM, no significant increase in resolution was observed. 




concentration of HP-β-CD was determined to be 20 μM.  
To further improve the resolution, ethanol was evaluated as an 
organic modifier. Ethanol increases the hydrophobicity of the surrounding 
solvent thereby modifying the interaction between the analyte and the 
cyclodextrin.20 Figure 2.4 (B) shows the relationship between ethanol 
percentage and the resolution between three adjacent peaks: ornithine 
and internal standard, internal standard and citrulline, citrulline and DBD-F 
byproduct. Although the resolution between the internal standard and 
citrulline peaks decreased with increasing ethanol, the resolution between 
the other peaks were greatly improved. Therefore, the optimized 
percentage of ethanol was determined to be 25%. An electropherogram of 
citrulline, ornithine, and the internal standards is shown in Figure 2.5. A 
basal rat brain microdialysis sample was also analyzed under the 
optimized separation conditions. The electropherogram is shown in Figure 
2.6. Ornithine and citrulline peaks were identified by spiking the 












Figure 2.4 Optimization of background electrolyte composition. (A) HP-β-
CD concentration optimization. X-axis is HP-β-CD concentration, and y-axls is 
the resolution between citrulline and the internal standard peak. (B) Ethanol 
percentage optimization. X-axis is ethanol percentage, and y-axis is the 


















































Figure 2.5 Electropherogram of 10 μM citrulline, ornithine, and the internal 
standard. Separation condition: 20 mM LTB, 25 mM HP-beta-CD, 25% EtOH, pH 










Figure 2.6 Electropherogram of a basal rat brain microdialysis sample. 
Separation conditions: 20 mM LTB, 25 mM HP-beta-CD, 25% EtOH, pH adjusted 
to 10.35. The ornithine and citrulline peaks were determined by spiking the 







2.4 Method Validation 
Reproducibility of the method was evaluated with and without the 
use of an internal standard. The standard sample with internal standard is 
derivatized with the method described in Section 2.2.3. Then the 
derivatized sample was injected five times and separated using the same 
batch of BGE. The results are shown in Table 2.1. The normalized result 
refers to the peak height (peak area) ratio of amino acids to internal 
standard. It indicates that reproducibility is improved by adding the internal 
standard. The peak area %RSD of citrulline was improved from 13% to 
10%, and %RSD of ornithine was improved from 18% to 6%.  
A calibration curve was obtained by using standard solutions of 
ornithine, citrulline and the internal standard over the concentration range 
of 0.2 to 10 μM. The measurement at each concentration was repeated 
three times. The calibration curve was plotted as the peak area ratio of the 
amino acid to the internal standard versus concentration. The  linear 
regression equation for ornithine peak area was y=0.2300x+0.0144 with 
R2=0.9976, and citrulline’s linear regression equation from is 
y=0.3068x+0.0091 with R2=0.971, where y is peak area ratio of citrulline to 
internal standard, x is concentration in μM, slope unit is μM-1.The limit of 
detection was measured as the lowest concentration that gave a signal-to-
noise ratio of 3. The LOD of citrulline was 9 nM and the LOD of ornithine 




2.5 In vivo Microdialysis Study 
The most commonly used seizure model to study epilepsy is the 
chemically induced seizure model. Our group has applied a 3-
mercaptopropinoic acid (3-MPA) induced seizure model, in which 3-MPA 
is administrated as chemical convulsant to induce seizures.21-25 Glutamate 
(Glu) is the major excitatory neurotransmitter in the brain, while γ-
aminobutyric acid (GABA) is the major inhibitory neurotransimitter. GAD 
(glutamic acid decarboxylase) is the enzyme that converts Glu to GABA. 
3-MPA is a competitive inhibitor of GAD. When 3-MPA is administrated, it 
decreases the GABA concentration in the brain and increases Glu 
concentration. This results an imbalance between GABA and Glu leading 
to seizures.26 In this project, 3-MPA was delivered through the 
microdialysis probe to induce the seizure, and the concentration change of 
citrulline and ornithine was monitored.  
In these studies, the animal was awake and freely moving. In 
contrast to studies using anesthetized animals, an awake animal study 
can better mimic the real biomarker changes in the brain, especially since 
the supplemental anesthesia can affect the concentrations of 
neurotransmitters in the brain. 
Figure 2.7 shows the concentration change of extracellular citrulline 
and ornithine in the brain during 10 mM 3-MPA dosing. The results show 




and the concentration of ornithine increased by ~100%, and both of them 
stay relatively leveled for ~3 hours. T-test was performed with the area 
under the curve (AUC) at each time point. This provides evidence that 
both the NOS pathway and arginase pathways are activated as a function 
of seizure activity. Even though arginase competes with NOS, NO is still 
produced during epileptic seizure.  
This data can be compared with that obtained in future studies 
investigating the role of oxidative stress in seizures, for example, 
electrocochleography (ECoG) seizure activity studies. It also can be 
correlated with the oxidative damage biomarkers such as 
malondialdehyde (MDA) to determine the damage due to oxidative stress 
in epileptic seizure, or correlated with how antioxidants such as 






Figure 2.7 Concentration changes of ornithine and citrulline during an 
epileptic seizure induced by 3-MPA. Red boxes indicate the administration period 













































A cyclodextrin-modified CE-LIF separation method with DBD-F 
derivatization was developed for citrulline and ornithine that exhibited good 
linearity, reproducibility and low detection limits. The microdialysis 
experiments described in this chapter prove that the seizure induced 
oxidative stress and that this results in an increase in the concentration of 
both citrulline and ornithine.. From the mechanism shown in Figure 2.1, 
this indicates that arginine participates in both the NOS and arginase 
pathways and the production of nitric oxide in the brain is also confirmed.  
The method and results described here will be compared with other 
studies of oxidative stress during seizures in the future, to elucidate the 
mechanism, damage and methods of treatment. Moreover, although this 
chapter is focused on citrulline and ornithine, the DBD-F derivatization and 
cyclodextrin modified CE separation can also be applied to the 
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3 LC-MS Method Development of Eicosanoids in 
Rat Colon Microdialysate to Study Inflammatory 
Bowel Disease 
3.1 Background 
3.1.1 Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a chronic relapsing 
inflammatory gastrointestinal (GI) tract disorder. It is one of the most 
prevalent GI tract diseases in the world and affects 1.4 million people in 
the US and 2.2 million people in Europe in total currently. 1-2 IBD has a 
peak incidence in 15-30 years old adults.3 It has two important subtypes, 
Crohn’s disease (CD) and ulcerative colitis (UC). They are mostly 
distinguished from each other by the inflammation tissue sites. In CD, 
inflammation spreads throughout the entire GI tract, while in UC, the 
inflammation is confined to the colon. Moreover, in CD, the inflammation 
infects all the GI tract layers, while in UC, the inflammation only involves 
mucosa and submucosa layers. The clinical symptoms of IBD, including 
bloody diarrhea, abdominal pain during bowel movement, fever, loss of 
appetite, and sequential weight loss, are mostly due to inflammation.4 
Chronic inflammation increases the risk of IBD developing into colorectal 
cancer approximately 18 fold.5 CD and UC have similar treatment plans 




therapies8 and enzyme modulators9,10. 
The pathogenesis of IBD involves three factors: genetic 
predisposition, environmental triggers, and inappropriate mucosal immune 
response. Nod2 gene mutations are the gene predisposition primarily 
responsible for IBD.4 IBD is more prevalent among Caucasians and 
Ashkenazi Jews. It has its highest incidence rate in northern Europe and 
North America. It is also clustered within families, with a reported 50%–
60% concordance of Crohn’s disease in identical twins.3 Environmental 
triggers include viral/bacterial infection and smoking. Interestingly, 
cigarette smoking shows different influences with regard to UC and CD. In 
CD patients, smoking exacerbates inflammation; however, non-smokers 
have a higher risk of getting UC.2,11 In healthy people, the gut can tolerate 
some amount of the nonpathologic antigens such as viral or bacterial; 
however, for those who have a genetic susceptibility toward IBD, the 
antigens induce an inappropriate mucosal immune response and cause 
IBD.3,12,13  
3.1.2 Enzyme Pathways 
In this section, we introduce the third factor—inappropriate mucosal 
immune response—in detail. The inflammatory response begins with 
CD4+ T-lymphocytes being recognized as nonpathologic antigens. These 
T-lymphocytes are called T-helper (Th) cells and are important in 




cells interact with Th cells, activating the Th cells that differentiate into Th1 
cells that secrete interleukin-2 (IL-2) and interferon gamma (IFN-γ). 
Similarly in patients with UC, Th cells differentiate into Th2 cells producing 
IL-5 and the transforming growth factor β (TGF-β).14 These cytokines 
induce the gene expression of several enzymatic pathways, such as 
cyclooxygenase (COX), lipoxygenase (LOX) and inducible nitric oxide 
synthase (iNOS). In healthy people, the inflammation is self-limiting, but in 
those with genetic susceptibility, it develops into the chronic inflammation 
of IBD. The exact mechanism of IBD is still not fully understood. The 
objective of the studies in this chapter is to investigate two of the 
enzymatic pathways, COX and LOX using in vivo microdialysis sampling. 
We chose 13 prostaglandins, thromboxane, hydroxyeicosatetraenoic acids 
and leukotrienes as the biomarkers for COX and LOX pathways. This 
chapter focuses on the development of a LC-MS/MS method to study the 
biomarkers in rat colon microdialysate. 
3.1.2.1 Cyclooxygenase 
Cyclooxygenases (COXs) are the enzymes involved in the three-
step metabolism of arachidonic acid (AA) to prostaglandins (PGs) and 
thromboxane (TXB). There are two major isoforms of COX, COX-1 and 
COX-2. COX-1 is known as “housekeeping” enzyme that is constitutively 
expressed in prostanoid-producing cells under normal physiological 




COX-2 is an inducible enzyme present that exists in inflamed tissues. The 
gene expression of COX-2 is very low in the healthy tissue. However, it  is 
secreted by inflamed tissues and mediates the inflammation response. 
Studies have shown the messenger ribonucleic acid (mRNA) expression 
of COX-1 remains normal while mRNA expression of COX-2 greatly 
increases during the acute inflammatory response.15  
COX first catalyzes AA oxidation to prostaglandin G2 (PGG2s). 
PGG2 are sequentially reduced to the prostaglandin H2 (PGH2). PGH2 are 
converted into various prostaglandins and thromboxanes, including 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α 
(PGF2α), TXB2, 8-isoprostaglandin F2α (8-isoPGF2α) and 6-
ketoprostaglandin F2α (6-ketoPGF2α) via different synthases.16,17 The 
detailed pathways are shown in Figure 3.1. The pro-inflammatory 
prostaglandins including PGD2, PGE2, PGF2α, TXB2, 8-isoPGF2α and 6-
ketoPGF1α were chosen as biomarkers of the COX pathway to monitor the 
IBD inflammatory response.18,19  
3.1.2.2 Lipoxygenase  
Similar to the behavior noted for COX, lipoxygenases (LOX) 
mediate the conversion of AA into hydroxyeicosatetraenoic acids (HETE) 
and leukotrienes (LTs). There are three common isoforms of LOX: 5-LOX, 
12-LOX and 15-LOX. LOX first catalyzes AA oxidation to 




HPETE, 12-HPETE and 15-HPETE. These HPETEs are unstable 
intermediates and are subsequently reduced to their corresponding 
HETEs, 5-HETE, 12-HETE and 15-HETE by glutathione peroxidase or 
microsomal glutathione S-transferases.  
In the 5-LOX pathway, 5-HPETE not only produces 5-HETE, but 
also produces LTA4. LTA4 is an unstable epoxide that can be further 
converted into the more stable products: LTB4, LTC4, LTD4 and LTE4. LTs 
are lipid signaling compounds that are important in modulating the 
inflammatory response.20 As shown in Figure 3.1, the more stable final 
products (LTB4, LTC4, LTD4, LTE4, 5-HETE, 12-HETE and 15-HETE) were 











Figure 3.1 Phospholipid degradation pathways catalyzed by COX, LOX 



































3.2.1 Chemicals and Reagents 
PGD2, PGE2, PGF2α, TXB2, 8-isoPGF2α, 6-ketoPGF1α, TXB2, LTB4, 
LTC4, LTD4, LTE4, 5-HETE, 12-HETE and 15-HETE were purchased from 
Cayman Chemicals (Ann Arbor, MI, USA). LC-MS grade formic acid and 
acetic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Acetonitrile (MeCN), calcium chloride dihydrate (CaCl2·2H2O), magnesium 
chloride (MgCl2), potassium chloride (KCl), and sodium chloride (NaCl) 
were purchased from Fisher (Fair Lawn, NJ, USA). Ethanol was received 
from Decon Labs, Inc (King of Prussia, PA, USA). Ultrapure water was 
prepared with a Milli-Q system (Millipore, Bedford, MA, USA) 
3.2.2 Solution Preparations 
Ringer’s solution used for microdialysis studies consisted of 145 
mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2 and 1.0 mM MgCl2.  PGs and TXB 
stock solutions were prepared by dissolving them into ethanol at a 
concentration of 1 mg/mL. The resulting solutions were stored at -80 oC . 
The standard solutions containing 5 μM PGs, LTs, TXB and HETEs were 
prepared in Ringer’s solution. For long-term storage (> 3 days), the 
standard diluted solutions were stored at −80 oC. For short-term storage (≤ 




3.2.3 LC-MS Condition 
3.2.3.1 LC Condition 
The LC separation system was a binary gradient system made up 
of two Shimadzu LC 20 ADxr pumps and a CBM-20A system controller. 
The LC column was a Phenomenex Kinetex XB-C18 column (100 mm 
long, 2.1 mm i.d., 1.7 μm particle size). The optimized separation was 
achieved by gradient elution. Solvent A consisted of 60 mM acetic acid. 
Solvent B was 100% acetonitrile containing 60 mM acetic acid. A linear 
gradient profile was employed as follows: 0–18 minutes, solvent B 
increased from 25 to 55%. Then it was increased to 60% and held there 
between 18 to 27.5 minutes; finally, the gradient was decreased back to 
25% of mobile phase B for 10 minutes to establish equilibrium in the 
column. (Figure 3.2) 
3.2.3.2 MS Detection 
Tandem mass spectra were acquired via a Thermo LTQ XL ion-trap 
mass spectrometer coupled with an ESI interface in the negative ion 
mode. The ESI source conditions were optimized to achieve the optimal 
ionization efficiency as follows: spray voltage at 4.5 kV, capillary temp at 
225 oC. For different analytes, the detection was divided into different 
segments based on the LC retention time to improve sensitivity. In each 
segment where MS/MS detection was utilized, the collision energy and 




window of m/z value that gives highest intensity. If the isolation width is too 
small, the peak height might be small. If the isolation width is too large, the 
noise can be high. The segments and corresponding optimized conditions 
are listed in Table 3.1. A diverting valve was utilized to guide the first 6.5 
min and the last 7.5 min eluents to waste. MS data were obtained and 











Figure 3.2 LC separation mobile phase gradient. Mobile phase A consists 
of an aqueous solution of 60 mM acetic acid. Mobile phase B is acetonitrile 






















Table 3.1 MS/MS detection conditions. The detection windows are divided 
into different segments based on elution time. The parent ions are identified by 
full scan. Isolation width, collision energy and product ions are optimized to 















Product Ions  
(m/z) 
1 0-6.50 To Waste 
2 6.50-9.83 6-keto 369.48 3.0 35 315.31, 333.32, 351.34 
3 9.83-12.83 
PGF,  
8-IsoPGF 353.45 1.0 25 335.34 
TXB 369.31 1.5 35 169.17, 195.18 
4 12.83-15.33 PGE, PGD 351.43 1.5 35 315.30, 333.31 
5 15.33-18.23 
LTD 496.50 3.0 35 351.32, 477.39 
LTE 439.50 2.5 35 420.32 
LTC 624.50 3.5 35 354.17, 272.17, 606.46 





319.42 1.0 30 219.3, 257.33, 301.35 




3.3 Method Development 
3.3.1 LC Separation Optimization 
Thirteen analytes with different properties were separated by 
reverse phase LC. The total analysis time was greater than one hour using 
isocratic elution. In order to reduce total analysis time, gradient elution was 
used. The gradient changed from 25 to 55% mobile phase B within the 
first 18 minutes to separate the PGs, TXB, LTC, LTD and LTE. The mobile 
phase B was then increased and held at 60% from 18−27.5 min to 
separate LTB and HETEs. At last the %B was changed back to 25% to 
establish equilibrium for the next run, ending at 37.5 min. A detailed 
gradient profile is shown in Figure 3.2. The LC column was an XB-C18 
column (100 mm long, 2.1 mm i.d., 1.7 μm particle size).  The column 
diameter and stationary phase particle size was small leading to column 
pressures that were too high for the Shimadzu 20 ADxr HPLC pumps. In 
order to maintain a lower column pressure at faster flow rates, acetonitrile 
was used as the organic phase instead of methanol because of its lower 
viscosity.  A flow rate of 0.12 mL/min was used in these studies. The 
injection volume was 10 μL. 
The goal of this chapter was to design a LC-MS method for the 
analysis of eicosanoids in colon microdialysis samples. The endogenous 
extracellular concentration of the eicosanoids is less than 20 nM, and 




volume available for LC injection is also limited (<15 μL). All of these 
challenges require a high sensitivity LC-MS method. 
In order to improve ionization efficiency and sensitivity, LC mobile 
phase modifiers were evaluated. Common ESI-LC-MS modifiers include 
volatile weak acids or weak bases. Examples include acetic acid, formic 
acid, and ammonium acetate. In most circumstances, weak acids are 
utilized for positive ionization mode. This is a straightforward solution 
because weak acids add positively charged hydrogen ions to the ESI 
spray droplets and protonate the analytes. 
In initial experiments, positive mode was assessed; however, 
higher baseline noise was observed in the positive mode as compared to 
the negative mode, which compromised the LOD. This is because more 
interfering compounds are ionized and detected in the positive ion mode. 
After switching to the more selective negative ionization mode, the 
baseline noise was reduced. The weak acids improved the limits of 
detection.  
Adding a weak acid to the mobile phase while applying a negative 
voltage is not as common as applying a positive voltage, but this 
phenomenon was observed before.21-23 Dalton et al. performed a 
systematic study using four different carboxylic acids: formic acid, acetic 
acid, propionic acid, and n-butyric acid as mobile phase modifiers.24 They 




mode ESI. Their results were as follows: Although formic acid diminished 
ionization, the other three weak carboxylic acids improved negative 
ionization efficiency. Among those three, acetic acid was the most 
effective.  
They also found that ionization efficiency varies along with different 
acid concentrations and target analytes. They proposed a “wrong way 
round” theory to explain this phenomenon. Small droplets are formed in 
the ESI ion source. The weak acids provided both excessive protons and 
their corresponding negative ions accumulated on ESI spray tip and 
droplet surface. In the negative ionization mode, a negative electric field 
was applied, which reduced H+ to hydrogen gas that evaporated from the 
droplets; hence, excessive negative ions were left on the droplet surface. 
This is how weak acids help improve negative ionization efficiency. Based 
on this hypothesis, they also investigated the relationship between gas-
phase proton affinities of carboxylic anions and their ionization efficiency. 
Formic acid has a Gibbs free energy of the formation from ions of 1415.0 ± 
8.4 kJ/mol; while acetic acid has 1427.0 ± 8.4 kJ/mol. Not surprisingly, 
acetic acid gave the best ionization efficiency.24  
We performed similar studies using formic acid and acetic acid. We 
added the same amount of formic acid or acetic acid in the mobile phase, 
and the ionization was conducted in the negative mode. As shown in 




With acetic acid, all 13 analytes gave a better response than that with 
formic acid. We also further optimized the concentration of acetic acid. As 
stated in Dalton’s paper, different analytes also responded differently 
under different concentrations. For the relatively better ionized analytes, 6-
ketoPGF, 8-isoPGF and PGE, the 23.5 mM concentration proved to be the 
most favorable. However, for the other analytes, 60 mM was better. Since 
the 6-ketoPGF, 8-isoPGF and PGE give higher response than the other 
analytes, we chose the high concentration of 60 mM acetic acid as the 
optimized mobile phase modifier condition. 
3.3.2 MS Detection Optimization 
For initial experiments, standard analytes were infused into MS, 
and detected in the full scan mode to identify the parent ions m/z. After the 
parent ions were determined, collision gas was applied to fragment the 
parent ions, and then the product ions were determined. Collision energy 
and isolation width were optimized to achieve the best sensitivity. In order 
to optimize the LODs, the most abundant 1–3 product ions in SRM 
detection and their different combinations were analyzed. The 
combinations with best S/N were chosen as the optimized SRM 
fragmentations. Table 3.1 summarizes the optimized MS conditions. 
In the in vivo study, the perfusate was Ringer’s solution. No matter 
what the standards were dissolved in, Ringer’s solution or in vivo 




salt. When such a large amount of salt goes into ESI-MS, it will cause ESI 
source capillary to clog and can also lead to ion suppression. In order to 
avoid this, we used a divert valve to elute the first 6.5 min and last 7.5 min 
of the eluent to the waste. The salt is not retained on the C-18 column and 
exits as waste in the first 6.5 minutes. 
In order to improve sensitivity, MS detection was divided into 
different segments based on LC elution time. Only one analyte was tried to 
be assigned to one segment; however, for analytes that co-eluted or that 
elute closely with each other, two or three analytes were assigned to one 
segment. For example, LTC, LTD, and LTE all eluted around 16-17 min, 
so they were assigned in a 15.33-18.23 min segment together. More 











Figure 3.3 Mobile phase modifier optimization-weak acid type 








































































Figure 3.4 Comparison of mobile phase modifier concentration on peak 
area. (20nM standards, N=3) * shows the result is significant in ANOVA F test at 



































































3.4 Method Validation 
3.4.1 Calibration Curve  
Standard solutions with 13 eicosanoids were prepared in Ringer’s 
solution by serial dilution to build calibration curves. The calibration range 
was 1-100 nM, and the seven calibration points were 1, 2, 5, 10, 20, 50, 
100 nM. Since analytes exhibit different degrees of hydrophobicity and 
different ionization efficiency, the linear range will be different for each 
compound. The calibration curve of TXB only had four points between 10-
100 nM; the calibration curves of PGD, 5-HETE, 12-HETE and 15-HETE 
had six points between 2-100 nM. All the other analytes used a seven-
point calibration from 1-100 nM. The calibration range and linear 
regression coefficients are listed in Table 3.2.  
The linear regression coefficients obtained using this method were 
not optimal. One of the reasons is that some of the analytes are 
hydrophobic, so they precipitated out or attached to vial walls during the 
serial dilution process. The predicted octanol-water partition coefficients 
(logP) of the 13 eicosanoids are listed in Table 3.3.25 Only 6-ketoPGF has 
a log P less than 1 (P=0.93), all the other analytes had a log P larger than 
1, which indicates they are hydrophobic. Also, the LTs and HETEs are 
more hydrophobic compared to PGs, since their log P values are larger 
than 5 while PGs log P values are around 2. This issue was addressed by 









Table 3.2 Calibration curves, their R2, and the calibration range, where x 





































A mixture containing10 nM standard solutions of the 13 analytes in 
Ringer’s solution was injected five times into the LC-MS to test 
reproducibility. The percent relative standard deviation (%RSD) results are 
shown in Table 3.4. The reproducibility of the peak area was better than 
that of peak height, so all further quantification was based on peak area. 
3.4.3 Chromatography 
A chromatogram of the 10 nM 13 standards is shown in Figure 3.5 
under the optimized separation and MS detection conditions discussed 
above. The LC system successfully separated most of the analytes. Only 
the LTC4, LTD4 and LTE4 peaks coeluted, but they have different 


























Figure 3.5 Extracted ion chromatograms of thirteen analytes (10 nM) 
dissolved in Ringer’s solution. Data acquired with Thermo Xcalibur software, 
peak identification used Genesis mode, and peak smoothing used Gaussian and 








In this chapter, we describe the successful development of an LC-
MS/MS method to separate and detect 13 PGs, LTs and HETEs.  The 
conditions were optimized to achieve the best sensitivity and LODs. 
However, the sensitivity and LOD of some analytes still was not adequate 
for the needs of current microdialysis studies. Further optimization of the 
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4 Effect of Cyclodextrins on Hydrophobic Analytes 
Recovery in Microdialysis 
4.1 Cyclodextrin  
4.1.1 Introduction 
In the last chapter, we developed a LC-MS method to study 13 
eicosanoids in rat colon microdialysates; however, there are some issues 
with from sample handling due to hydrophobicity of the eicosanoids, 
including bad reproducibility and high LODs and sample loss during serial 
dilution. In this chapter, we added cyclodextrin to the microdialysis 
perfusate to solve these issues. 
Cyclodextrins (CD) are a class of cyclic oligosaccharides produced 
by starch enzyme digestion. Cyclodextrins consist of five or more (α-1,4)-
linked α-D-glucopyranose units. The natural occurring cyclodextrins have 
six to eight glucose rings and are called α-, β-, γ-cyclodextrins, 
respectively. Cyclodextrins with less than five or more than eight glucose 
units do not exist in nature and are produced in very low yield when 
synthesized.1,2  
Due to the conformation of the glucose units, CDs exhibit a hollow 
truncated cone shape. Figure 4.1 shows the chemical structure and 3D 
structure of a β-CD. The hydroxyl groups contribute to the hydrophilic 




ethereal oxygen atoms, which makes the central cavity lipophilic.1,3  
Due to the hydroxyl groups on the hydrophilic outer layer, 
cyclodextrin is soluble in water. However, in the crystalline state, the 
hydroxyl groups also form strong intermolecular hydrogen bonds that 
render low solubility. The solubility of α-, β-, and γ-cyclodextrins in pure 
water at 25 °C are 145, 18.5 and 232 mg/mL, respectively.4 In addition to 
the natural cyclodextrins discussed above, there are also several 
cyclodextrin derivatives, such as hydroxylpropyl β-, γ-cyclodextrin 
derivatives, methylated β-cyclodextrin derivatives and sulfobutylether β- 
synthesized cyclodextrin derivatives. These usually have better solubility 
than native cyclodextrin, because other groups substitute the hydrogen so 
there are no longer intermolecular hydrogen bonds. For example, 2-
hydroxypropyl-β-cyclodextrin has a solubility of > 600 mg/mL in water at 












Figure 4.1 Structure of cyclodextrin. (Left) chemical structure of β-
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4.1.2 Inclusion Complex 
Cyclodextrins have very important applications in the 
pharmaceutical industry and in separation science, because they can form 
inclusion complexes with other small molecules through hydrophobic 
interaction, hydrogen bonding, electrostatic interactions and van der 
Waals interactions. In an aqueous solution, one or more lipophilic small 
molecules, usually aromatic compounds, can go into the lipophilic cavity of 
cyclodextrin, forming a “host-guest” inclusion complex. Van der Waals 
forces and hydrogen bonding are the major forces involved in the inclusion 
process rather than covalent bonding.2  
The inclusion complex has an extremely rapid equilibrium with host 
cyclodextrin and its small guest molecule or molecules.  
cyclodextrin + guest molecule ↔ inclusion complex 
The stoichiometry may vary with different size and properties of the 
cyclodextrin and guest molecules. The most common stoichiometry is 1:1 
and 1:2 guest molecule/cyclodextrin. Moreover, the inclusion process is 
able to occur on different parts of the guest molecule based on structures 






In the pharmaceutical industry, cyclodextrins have been used as a 
functional excipient to enhance solubility, bioavailability stability and flavor 
of drugs.  More than 30 drugs on the market contain cyclodextrins. They 
are considered safe since hydrophilic cyclodextrins are not absorbed in 
the GI tract after an oral dose. However, the GI tract can absorb lipophilic 
cyclodextrins such as methylated cyclodextrins, so they are toxic and their 
pharmaceutical application is limited.6 In separation science, cyclodextrins 
are used in liquid chromatography (LC) and capillary electrophoresis (CE), 
particularly for chiral separations.3,7  
4.1.3.1 Pharmaceutical Application 
Drugs delivery is easier if the administered drugs are soluble in 
aqueous solutions. On the other hand, most biological membranes are 
lipophilic. In order to achieve transcellular drug transport, drugs are 
preferred to be lipophilic. Therefore, the ideal drug molecule is both 
hydrophilic and lipophilic. However, not all the drugs possess both 
hydrophilic and lipophilic sites. There are several formulation strategies 
that can help solve this issue, and cyclodextrin addition is one of them.6  
Higuchi and Connors proposed the classic phase-solubility 
classification.8 They classified the complexes according to their substrate 
solubility into Type A and Type B. Type A are the ones whose solubility 




cyclodextrin derivatives. Type B are the ones whose solubility is still 
limited with more cyclodextrin, and at a certain point, cyclodextrin starts to 
precipitate out along with the drug. This is common with the less soluble 
natural cyclodextrins. In addition to Type A and B, Higuchi and Connors8 
also developed different subtypes, which include: AL, AP, AN, BI and BS.  






























4.1.3.2 Separation Application 
Cyclodextrins exhibit chiral discrimination properties due to their 
large number  of chiral centers. For example, α-, β- and γ-CD have 30, 35 
and 40 chiral centers, respectively.10 Cyclodextrins respond differently to 
different chiral guests and are used in LC and CE as chiral selectors.7  
In LC, cyclodextrin is bonded to the stationary phase or added to 
the LC mobile phase. There are several commercially available chiral LC 
columns, such as Astec CYCLOBOND from Supelco Analytical, and 
ChiraDex from Agilent. Cyclodextrin chiral separations can be performed 
using normal phase, reverse phase, or hydrophilic interaction 
chromatography (HILIC).11,12 In capillary electrophoresis, cyclodextrins are 
usually directly added to background electrolyte (BGE). β-cyclodextrin is 
the most commonly used cyclodextrin for CE chiral separations. It can be 
used in the simple capillary zone electrophoresis (CZE mode) to achieve 
affinity CE13 or added along with sodium dodecyl sulfate (SDS) to be used 
in the CD-micellar electrokinetic chromatography (CD-MEKC) mode.14 
Besides adding natural cyclodextrins or neutral cyclodextrin derivatives, 
positively or negatively charged cyclodextrins are also widely applied for 
CE separations. Similarly when adding charged micelles in MECK, the 
charged CDs also migrate towards the outlet (or inlet) of a capillary and 
improve resolution.3,15 In Chapter 2, we added CD to the BGE in capillary 





4.1.4 Objective of Applying Cyclodextrin in Colon Microdialysis 
In Chapter 3, we developed a LC-MS method to study 13 
eicosanoids for the analysis of rat colon microdialysate samples; however, 
it was not sufficient for the in vivo studies. First, the reproducibility and 
LODs were not optimal. In particular, because the eicosanoids exhibit low 
aqueous solubility, they precipitated out of the solution or attached to 
sample vial wall during sample preparation, especially in serial dilution. 
Also, the recovery of eicosanoids in the microdialysis experiment is 
relatively low. Therefore, most of the analytes in colon microdialysates 
relevant to these studies cannot be detected.  
In order to solve these issues, cyclodextrin was added into the 
perfusate. It first improved the solubility of eicosanoids, so it stabilized 
their concentration in solution and improved reproducibility and sensitivity. 
Second, in the in vivo sampling process, it improved recovery by forming 
inclusion complexes with the small molecules. 
4.2 Experimental 
4.2.1 Chemicals and Solution Preparations 
In addition to the reagents listed in chapter three, (2-
hydroxypropyl)-β-cyclodextrin (HP-β-CD) was purchased from Sigma-
Aldrich (St. Louis, MO, USA). 




as described in Chapter 3. It was diluted to a concentration of 100 nM with 
Ringer’s solution as the standard solution of an in vitro experiment. HP-β-
CD was dissolved and diluted into 2, 4 and 6 mM with Ringer’s solution as 
the perfusate of in vitro and in vivo experiments 
4.2.2 Microdialysis Probe Fabrication 
The linear microdialysis probe in this chapter was fabricated by 
threading two pieces of polyimide tubing into one piece of semipermeable 
membrane.  Then the membrane was attached to the tubing by UV glue. 
The next two sections describe the fabrication of the  two different linear 
probes that were evaluated in these studies. 
4.2.2.1 PAN Membrane Probe Fabrication 
The PAN membrane is transparent; hence, the fabrication is 
straightforward.  Specifically, a 1.4 cm piece of PAN (340 μm o.d. and 240 
μm i.d.) membrane was cut by a pair of sharp scissors and then two 
pieces of 10 cm polyimide tubing (163 μm o.d. and 122 μm i.d.) were 
inserted into the membrane 0.5 cm from both sides. In this way, the 
effective probe length was 0.5 cm. A microscope and ruler was used to 
ensure the exact positioning.  A small droplet of UV glue was applied on 
the seam between the membrane and polyimide tubing. A small portion of 
the UV glue went into the tubing due to capillary action. Microscope 
observation was needed to ensure the UV glue did not go in too far 




glue on its seam was then put under a UV lamp for 30 seconds, or longer 
if necessary, until the UV glue was fully cured. Then same UV glue 
application procedure was repeated on the other side. Figure 4.3 shows 
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4.2.2.2 PES Membrane Probe Fabrication 
Most of the procedure for PES membrane probe fabrication was 
identical to that of PAN. The only difference was that a PES membrane is 
opaque, so the exact length had to be marked first. Specifically, 1.4 cm of 
PES (270 μm o.d. and 200 μm i.d.) membrane was cut by the sharp 
scissors and a Sharpie was used to mark the 0.5 cm positions on both 
polyimide tubing (163 μm o.d. and 122 μm i.d.). Then the polyimide tubing 
were inserted into the membrane to the exact marker position and glued 
by UV glue.  
4.2.3 In vitro microdialysis recovery experiment 
The in vitro experiment set up used in these experiments is 
illustrated in Figure 4.4. About 2 mL of a 100 nM standard solution 
dissolved in Ringer’s solution containing the eicosanoids was prepared in 
a glass vial. The glass vial was placed on a magnetic stir hot plate to keep 
the solution at 37 oC and stirred continuously. The dialysis membrane was 
submerged in the standard solution. The probe inlet was connected to a 1 
mL syringe pump that was used to introduce the perfusate through the 
probe at a flow rate of 1 μL/min. Glass autosampler vial inserts (silanized 
glass inserts preferred) were used to collect dialysate from the outlet every 
15 min. Plastic vials were not used to prevent losing hydrophobic analytes 











Figure 4.4 In vitro microdialysis experiment setup. The standard solution 
dissolved in Ringer’s solution is kept at 37 oC and stirred continuously. A syringe 
pump is used to pump the perfusate (Ringer’s solution) through the probe at a 







4.2.4 Rat Surgery and In Vivo Microdialysis Sample Collection  
All animal experiments were performed in accordance with the local 
Institutional Animal Care and Use Committee. The soft tissue linear 
microdialysis probes were fabricated in our lab as described in the 
previous section. All animal experiments were performed on female 
Sprague-Dawley rats weighing from 150-350 g. Female rats were utilized 
because they have thicker mucosa layer of the colon. 
Rats were anesthetized in an isoflurane chamber. Supplemental 
isoflurane was administered throughout the entire surgery and experiment 
via a vaporizer. The rat body temperature was regulated at 37 ºC by a 
PhysioSuite temperature probe and heating pad (Kent Scientific 
Corporation, Torrington, Connecticut, USA). The rat was shaved around 
the abdomen after it was fully anesthetized. 
An incision was made along the abdomen midline. The colon was 
gently identified and exposed for a cannula implantation. The colon was 
flushed with the saline solution to remove fecal particles. A 25-gauge 
needle was used as the microdialysis probe cannula and inserted into 
mucosa layers or lumen of the colon. The microdialysis probe was 
threaded through the needle, and then the needle was removed from the 
tissue. Tissue glue was applied on the probe and colon to secure the 
probe to the implantation point during the whole experiment. 




BASi syringe pump (Bioanalytical Systems Inc., West Lafayette, IN, USA) 
at a 1 μL/min flow rate. Dialysate was collected every 15 min manually, 
and analyzed by the LC-MS method  described in chapter three, or stored 
at -80 oC in the freezer. 
4.3 Results and Discussions 
4.3.1 Solubility and Reproducibility Improvement of Microdialysis 
Recovery Using Cyclodextrin 
Most of the eicosanoids studied in this project are hydrophobic; 
they were recommended for dissolution in ethanol or other organic 
solvents. When prepared as high concentration stock solutions, they were 
dissolved in ethanol. However, microdialysis perfusates, such as saline or 
Ringer’s solution, are aqueous solutions. In Chapter 3, low concentration 
standard solutions were prepared by dissolving the analytes in Ringer’s 
solution. When performing the serial dilution, a large amount of the 
hydrophobic analytes was lost during each dilution, so the limit of 
detection (LOD) was only 10 nM. The limits of detection and reproducibility 
were improved with the methods described below. 
In order to prevent the loss of hydrophobic analytes during sample 
preparation, the solubility of the analytes needed to be improved. A 
straightforward way used to handle this has been to dissolve the 
compounds in organic solvents. However, this method could not be 




would diffuse into the tissue and caused tissue damage or inaccurate 
results. Another way to improve solubility of hydrophobic compounds is to 
add cyclodextrin, as mentioned in the introduction. Soluble cyclodextrin 
derivatives can improve the solubility of hydrophobic compounds.  
We chose 2-hydropropy-β-cyclodextrin (HP-β-CD) as an additive to 
the perfusate. Three concentrations (2 mM, 4 mM and 6 mM) of HP-β-CD 
were studied. They were all prepared in Ringer’s solution. The analytes 
were then serial diluted with this cyclodextrin containing Ringer’s solution 
to prepare 1, 2, 5, 10, 25, 50, 100 nM standard solutions of the 13 
eicosanoid analytes. They were analyzed with the LC-MS method 
developed in chapter 3 to build a calibration curve and to determine LOD. 
Each sample was injected three times.  
R2 values of each calibration curve are shown in Table 4.1 and the 
LODs are shown in Table 4.2. The percent relative standard deviation (% 
RSD) by injecting 10 nM of standard solution five times was also 
determined. (Table 4.3) These results show that the LOD, R2 and %RSD 
were all improved by adding cyclodextrin. Higher concentrations of CD 
further improved the results, but the difference between each 

























Table 4.2 Limits of detection (nM) determined for different sample 














Table 4.3 Percent relative standard deviation of LC-MS response of a 10 







4.3.2 Microdialysis Membrane Optimization to Improve Relative 
Recovery 
In addition to improving solubility, cyclodextrin has an even more 
important function in this project: improve microdialysis recovery. As noted 
in Chapter 1, relative recovery (RR) is defined as  
RR = !!
!!
                        (equation 1.2) 
Cd is the concentration in the dialysate and Cs is the concentration in the 
extracellular fluid. 
Relative recovery is also defined as: 
RR = 1 − exp  [− !
!! !!!!!!!!
]     (equation 1.3) 
where Qd is the flow rate of the perfusate, Rd is the mass transport 
resistance of dialysate, Rm is the mass transport resistance of the 
membrane, and Re is the mass transport resistance of extracellular space.  
Therefore, membrane material is one of the parameters that can 
change the microdialysis recovery. Common semipermeable membranes 
in microdialysis include polyacrylonitrile (PAN) polyethersulfone (PES), 
polyarylethersulfone (PAES), cuprophan (CUP), and cellulose acetate. 
PAN is the first choice of linear probe membranes in our lab, because it 
has a thicker wall and is more rigid (340 μm o.d. and 240 μm i.d.). It 




and it lasts longer in the in vivo experiments, especially for long-term 
awake animal studies. Moreover, PAN membrane is transparent, so the 
fabrication is easier and the accuracy of length is better.  
First, we investigated PAN as the probe membrane. We used the in 
vitro experiment setup illustrated in Figure 4.4 to study the microdialysis 
relative recovery. The collected dialysates were analyzed by the LC-MS 
method developed in Chapter 3. Although PAN has many advantages with 
regards to probe fabrication and in vivo studies, the recovery obtained with 
the PAN membrane probe was very low. This is because PAN is 
negatively charged16 and repels that analytes from the membrane wall. 
Also, Yeping Zhao et al have also indicated that the thicker membrane 
wall decreased the microdialysis recovery.16 As can be seen in Figure 4.6, 
the relative recoveries of PGs and TXB were between 20 and 30% and 
LTs were between 10 and 25%. The HETEs had the lowest recovery rate 
of less than 10%. 
Due to the low recovery exhibited by the PAN membranes and PES 
membranes (270 μm o.d. and 200 μm i.d.) were investigated next. The in 
vitro experiment results showed Figure 4.6, PES membrane successfully 
improved the recovery of the hydrophobic LTs and HETEs. (Figure 4.5) 










Figure 4.5 Relative recoveries achieved with PAN and PES membranes. * 
shows the result is significant in student t-test at p=0.05. ** shows the result is 






























































4.3.3 Microdialysis Relative Recovery Improvement by Cyclodextrin 
Another approach to improve microdialysis recovery is to add 
affinity agents to the perfusate. Julie Stenken’s group has performed 
extensive research on this. They added cyclodextrins, antibodies, and 
antibody linked flow cytometry beads into the perfusate to improve the 
recovery of small molecules, peptides and proteins.17-21 This is because 
the trapping agents were able to interact with the corresponding analytes, 
so the concentration of the target analytes near the inner wall of the 
semipermeable membrane was reduced leading to a steeper 
concentration gradient. Microdialysis is a concentration gradient driven 
diffusion process. When the concentration gradient is increased, the 
relative recovery is also increased.16 Trapping agents were chosen based 
on the structure of the target analytes. Cyclodextrins form inclusion 
complexes with small molecules that contain a hydrophobic and 
hydrophilic part and preferably an aromatic ring.19 Antibodies were utilized 
to improve the recovery of corresponding peptide and proteins.17,18,20 
According to Stenken’s research, a higher concentration of affinity 
reagent does not directly relate to a higher recovery rate19; therefore, an 
optimum CD concentration needed to be determined. In order to 
investigate this, 2, 4, and 6 mM HP-beta-CD samples were dissolved in 
Ringer’s solution and perfused through the probe. The concentrations 





In vitro study results are shown in Figure 4.6. It can be seen that 
the relative recovery rates were greatly improved by adding cyclodextrin. 
By increasing the CD concentration from 0 to 4 mM, the relative recoveries 
also increased. When we continued adding CD at concentrations above 4 
mM, the relative recovery decreased. This was consistent with Julie 
Stenken group’s study.19 They investigated ibuprofen’s recovery 
improvement by adding CD, and observed that with higher concentrations 
of CD, the recovery decreased. However, there is no clear explanation on 
why this happens. It might be due to the CD’s interaction with the 
membrane, or the inclusion complex’s conjugation with each other.19  
Another thing that needs to be noted is that if the CD goes into ESI 
ion source, it can result in ion suppression and reduce the sensitivity of the 
analytical method. Therefore, we employed a divert valve to guide the 
eluent for the first several minutes into a waste reservoir to reduce the 
amount of CD going into the mass spectrometer. However, the efficiency 
of this process still needs to be studied further. Therefore, the effect of 
sample matrix on the ESI-MS response was also evaluated. In this case, 
standard solutions containing 10 nM of 13 eicosanoid analytes were 
prepared in Ringer’s solution and 2 mM, 4 mM, and 6 mM HP-beta-CD 
were in Ringer’s solution. They were analyzed by the LC-MS system. The 




when divert valve was used. In contrast, low concentrations (2 mM) of CD 
improved the MS signal of hydrophobic LTs and HETEs. This might be 
because CD can improve eicosanoids solubility and reduce the amount of 
eicosanoids precipitated or attached to autosampler vial walls. After 
considering all results, 3 mM of CD in Ringer’s solution was chosen as the 










Figure 4.6 Relative recovery results for different concentrations of HP-
beta-CD dissolved in perfusate. The recovery was measured with 100 nM 
analytes in the perfusate. * shows the result is significant in ANOVA F test at 





















Figure 4.7 Sample matrix effect study results. 10 nM standard solutions 
were prepared in 0, 2, 4, 6 mM of HP-beta-CD containing Ringer’s solution. 
ANOVA test was performed, the results of all analytes are significant in ANOVA 
F test at alpha=0.05. Student t-test was performed between Ringer’s and 2 mM 































































4.3.4 In vivo Colon Microdialysate Analysis 
One in vivo study was performed to test this method. The 
microdialysis probe was implanted into a mucosa layer of a rat colon and 3 
mM HP-beta-CD was perfused through the probe at a flow rate of 1 
μL/min. The dialysate was injected into LC-MS and analyzed by the 
previously described method. The chromatograms are shown in Figure 
4.8. Six out of 13 analytes were detected. Although not all the analytes 
were above the LOD, this sample was from a healthy rat without any 
induced inflammation. The target analytes are inflammation biomarkers 
and we expected to see low or no response of them. In the future studies, 
after inducing inflammatory bowel disease in the rats, the concentrations 

















RT: 14.58 - 29.80












































TIC F: ITMS - c ESI SRM ms2 
319.42@cid25.00 
[218.80-219.80, 256.83-257.83, 
300.81-301.81]  MS 
20150526-Inj2
NL: 2.70E1
TIC F: ITMS - c ESI SRM ms2 
624.50@cid35.00 
[253.67-254.67, 271.67-272.67, 
605.96-606.96]  MS 
20150526-Inj2
NL: 4.83E1





TIC F: ITMS - c ESI SRM ms2 
439.50@cid35.00 
[419.82-420.82]  MS 
20150526-Inj2
NL: 1.09E3
TIC F: ITMS - c ESI SRM ms2 
319.42@cid25.00 
[218.80-219.80, 256.83-257.83, 
300.81-301.81]  MS 
20150526-Inj2
RT: 7.26 - 22.23 SM: 7G

































TIC F: ITMS - c ESI SRM ms2 
369.48@cid35.00 
[314.81-315.81, 332.82-333.82, 
350.84-351.84]  MS 
20150526-Inj2
NL: 8.14
TIC F: ITMS - c ESI SRM ms2 
335.47@cid25.00 
[194.66-195.66]  MS 
20150526-Inj2
NL: 9.06E1





TIC F: ITMS - c ESI SRM ms2 
353.45@cid25.00 
[334.84-335.84]  MS 
20150526-Inj2
TXB2 20 nM 
6-keto PGF1α 3 nM LTC4 
PGE2 8 nM 
LTB4 2 nM 
15-HETE 14 nM 
LTD4 
LTE4 
8-Iso PGF2α PGF2α 
5-HETE 
12-HETE 






This chapter describes the continued optimization of the method to 
study eicosanoids in rat colon microdialysates. We added cyclodextrin, 
which not only improved microdialysis recovery, but also improved the 
solubility of eicosanoids to reduce sample loss. We also changed the 
membrane material from PAN to PES. With these efforts, the microdialysis 
recovery was successfully improved from 5–30% to 40–85% and some of 
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5 Enzyme Facilitated Deconjugation to Study 
Stability of Antibody Drug Conjugates 
5.1 Introduction 
5.1.1 Antibody Drug Conjugates 
5.1.1.1 Cancer and Cancer Therapy 
Cancer represents one of the leading causes of death in the world. 
The American Cancer Society’s annual report, Cancer Facts and Figures 
2015, states that in the US alone, there will be “1,658,370 new cancer 
cases diagnosed and 589,430 cancer deaths.”1 Cancer treatment has 
become a major focus in academic world and pharmaceutical industry. 
Common cancer treatments include surgery, radiation therapy, 
chemotherapy, and precision medicine.  
Most cytotoxic anticancer drugs are nonspecific, which means they 
not only target the fast growing cancer cells but also healthy tissues. Side 
effects often include hair loss, fatigue, infection, memory or concentration 
problems, nausea, and vomiting. They also have a narrow therapeutic 
window, and they are usually dosed near their maximum tolerated dose 
(MTD). This limits their efficacy and can lead to multidrug resistance.2,3 
Monoclonal antibodies (mAb) are a type of cancer therapy that has 
high specificity and can reduce the side effects of chemotherapy. mAbs 




kDa. The antibodies  bind to specific antigens on the surface of the tumor. 
There are several commercially available mAb therapies, including 
Avastin®, Rituxan®, and Herceptin®. Although mAbs exhibit high 
specificity and lower side effects than cytotoxic anticancer drugs, it also 
has the disadvantage that its potency is limited.4,5  
5.1.1.2 Antibody Drug Conjugates 
To improve the cytotoxic drug’s specificity while maintaining its 
potency, antibody drug conjugates (ADCs), have drawn a lot of attention in 
recent years. The basic idea behind ADCs is to bind a nonspecific high 
potency drug with a site-specific monoclonal antibody, so it can be directly 
delivered to the tumor site. There are three major compartments of ADC: 
monoclonal antibody, cytotoxic drug, and a linker that combines them.  
The first generation ADC was gemtuzumab ozogamicin 
(Mylotarg®), which was designed to treat acute myeloid leukemia. The US 
Food and Drug Administration (FDA) approved Mylotarg® in 2000.6 
However, it was withdrawn from the market later because its linker was 
not stable, so the ADC was not did not survive systematic circulation and 
the cytotoxic drug was released too fast.7 The second generation of ADCs 
featured improved stability through more stable linkers. The FDA approved 
second generation ADC drug includes ADCETRIS® (brentuximab vedotin) 





5.1.2 Anatomy of an ADC 
The three major components of the ADC are shown in Figure 5.1. 
5.1.2.1 Antibody 
The most critical requirement of the antibody component of ADC is 
high specificity. The antibody must specifically bind to the tumor antigen 
on the surface of the cancer cell. After binding, the ADC is internalized into 
the cancer cell and the cytotoxic drug is released in the lysosomal 
compartment. If the antibody does not exhibit (or show) high specificity, it 
can also bind to normal tissue and result in toxicity to healthy tissue.2,10  
5.1.2.2 Linker 
The linker connects cytotoxic drug with the monoclonal antibody 
(mAb). The linker has to be stable during systemic circulation until the 
ADC reaches the tumor site. There are currently two types of linkers: 
cleavable linkers and non-cleavable linkers. 
 Cleavable linkers are the most common. These include chemically 
labile linkers (acid labile linkers and disulfide linkers) and enzyme labile 
linkers (protease cleavable linkers). The pH of blood is between 7.3–7.5, 
while endosomes and lysomes exist in an acidic pH of 4.5–6.5. The acid 
labile linkers are stable at neutral pH and therefore do not degrade in 
systemic circulation. However, following internalization into tumor cells, the 
linker is cleaved and the cytotoxic drug is released. The disulfide linkers 




tumor cells contain a much higher concentration of glutathione than that of 
blood, so the disulfide linkers are stable in blood circulation. After the 
ADCs are internalized by the tumor cells, the disulfide linkers are reduced 
and cleaved from mAb by the high concentration of glutathione. Enzyme 
labile linkers are more stable than chemically labile linkers in systemic 
blood circulation. They are engineered to be cleavable by lysosomal 
proteases. The linker of the model ADC in this project is a protease labile 
linker. Each model ADC has two valine-citrulline linkers that can be 
cleaved with cathepsin B, a cysteine protease. 
The non-cleavable linkers are those that are still connected to toxin 
after internalization. They are very stable in blood circulation; however, the 
drawback is that cytotoxic drugs cannot diffuse into neighboring tumor 
cells. Therefore, the ADCs with non-cleavable linkers usually show less 
potency.3,10  
5.1.2.3 Cytotoxic Drug 
The cytotoxic drug part on an ADC must exhibit high potency. It 
must have a good free drug half-maximal inhibitory concentration (IC50) 
that is usually in the sub-nano molar range. Also, in order to be 
successfully connected to the antibody, it needs to have suitable functional 
groups for connection, and it must remain stable in circulation until ADC 
reaches the tumor sites. The mechanism of drug action varies depending 




double-strand strand scission (monomethyl auristatin E (MMAE)), and 










Figure 5.1 Three major compartments of antibody drug conjugates: 
monoclonal antibody, linker and small molecule cytotoxic drug. 
  




5.1.3 Analysis of ADC 
Since ADC is a combination of the three components introduced 
above, the complexity of the drug is greatly increased compared to either 
mAb or small molecule cytotoxic drug alone. The linkage site and the 
chemical properties of different mAbs and cytotoxic drugs will greatly 
affect the physicochemical properties of ADCs as well as the applicable 
analytical methods. The analytical methods that are applicable for the 
native parent mAb cannot be directly applied to the ADC. And for each 
different ADC, new analytical methods are needed. Information critical to 
clinical efficacy such as drug potency, drug and linker stability, drug to 
antibody ratio (DAR), drug distribution, size variant needs to be 
determined with analytical/bioanalytical methods.11,12 The following is a 
brief summary of the current analytical methods that are applicable to 
ADC: 
The simplest ADC analysis method is LC-UV. The mAb has Amax at 
~280 nm and the cytotoxic drugs their own Amax based on the structure.11 
LC-UV analyses are performed to determine drug stability and DAR.13 In 
order to determine size variation, size exclusion chromatography (SEC)14 
and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)15 are commonly used. The drug distribution term here refers to the 
fragments of antibody that contain different numbers of cytotoxic drug. 




ionization (MALDI), electrospray ionization (ESI), or time-of-flight (TOF) is 
used to determine drug distribution.16-18 
In this project, we focused on the analysis of the small molecule 
cytotoxic drug attached to the antibody. The challenge is that the 
molecular weight (MW) of the small molecule drug (1.5 kDa) is quite 
different from that of the antibody (150 kDa). It is therefore hard to 
accurately determine the degradation on the small molecule after it is 
linked to a large protein using separation methods that are based on size 
such as SDS PAGE or SEC.  
5.1.4 Objective 
In this project, we used enzyme deconjugation to cleave off the 
small molecule cytotoxic drug from ADC prior to analysis. We were able to 
directly investigate the degradation of small molecule toxins with the LC-
UV method. One application of this method is to study the stability of the 
model ADC under different conditions. There are two types of conditions 
that were studied: (1) degradation in the presence of conjugation reagents 
left over and (2) the effect of formulation excipients. 
5.2 Experiment 
5.2.1 Reagents and Materials 
Acetonitrile (ACN, HPLC grade) was purchased from J. T. Baker 
(Phillipsburg, NJ, USA). Trifluoroacetic acid (TFA) and histidine acetate 




water was obtained from an in-house Milli-Q system (Millpore, Billerica, 
CA, USA). Cathepsin B (human liver) was received from EMD Millipore 
(Billerica, MA, USA). Cathepsin L (human liver) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Bromelain was received from Fisher 
Scientific (Pittsburgh, PA, USA). Pepsin from porcine gastric mucosa was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Trypsin (MS grade) 
was purchased from Thermo Scientific (Waltham, MA, USA).  Cathespin D 
(human liver) and α-chymotrypsin (bovine pancreases) were purchased 
from Alfa Aesar (Ward Hill, MA, USA). 
Sodium acetate, sodium citrate monobasic, D-(+)-trehalose 
dehydrate, N,N-dimethylacetamide (DMA), N,N-dimethylformamide (DMF), 
dimethyl sulfoxide (DMSO), hydrogen peroxide solution 30 % (w/w) in 
H2O, L-methionine sulfoximine (MSX), DL-dithiothreitol (DTT), (L)-
dehydroascorbic acid (DHA), N-acetyl-L-cysteine (NAC), and 
ethylenediaminetetraacetic acid tetrasodium salt dihydrate (EDTA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium phosphate 
monobasic monohydrate was purchased from Fisher Scientific (Pittsburgh, 
PA, USA). Sodium chloride (NaCl) and lactose monohydrate were 
purchased from EMD Millipore (Billerica, MA, USA). Sucrose and 
polysorbate 20 were purchased from Spectrum Chemical Manufacturing 
Corp (Gardena, CA, USA). Tris(2-carboxyethyl)phosphine hydrochloride 




Aesar (Ward Hill, MA, USA).   Sodium tartrate dehydrate was purchased 
from GFS Chemicals, Inc. (Powell, OH 43065) L-arginine, free base was 
purchased from Amresco (Solon, OH, USA). 50% sodium hydroxide 
solution (NaOH), hydrochloric acid (HCl 36.5%-38.0%), and benzyl alcohol 
were purchased from Avantor Performance Materials (Center Valley, PA, 
USA). 
ADC samples and the active free drug standards in this study were 
provided by Genentech (South San Francisco, CA, USA). 
5.2.2 Compatibility Study Procedure 
The model ADC sample was dissolved in 20 mM histidine acetate 
buffer (pH 6) at 50 mg/mL. The conjugation reagents and/or formulation 
excipients were dissolved in deionized water and pH adjusted with 
hydrochloric acid and/or sodium hydroxide. 25 µL of the conjugation 
reagent or excipient was added to 25 µL model ADC sample. The vial was 
put in a 40 oC, 75% humidity oven to incubate for either one or seven days. 
5.2.3 Enzyme Digestion Procedure 
The ADC samples were digested by aliquoting 50 µL of the ADC 
solution and 25 µL of bromelain (1.0 mg/mL in water) in a vial and 
incubating for 8 hours at 40 °C. Following incubation, the protein was 
precipitated by adding 150 µL ACN. The precipitated samples were then 
centrifuged at 13,000 rpm for 10 minutes, and then the supernatant was 




were prepared in ACN:water (1:1) diluent at a concentration of 0.1 mg/mL. 
5.2.4 LC-UV Conditions 
LC analyses were performed using Agilent 1200 system (Agilent, 
Santa Clara, CA) equipped with quaternary pump, vacuum degasser, 
auto-sampler, column thermostat, and a diode array detector. Empower  
(Waters, Milford, MA) was used to collect and process the data. The 
sample was analyzed by using a Poroshell SB-Aq column (150 × 3.0 mm, 
2.7 µm, Agilent, Sunnyvale, CA, USA). Initial conditions were set at 80% 
solvent A (0.05% TFA in water) and 20% solvent B (ACN). Solvent B was 
increased to 50% in 20 minutes using a linear gradient and then to 90% in 
10 minutes. Solvent B was held at 90% for 5 min followed by a 
reequilibration step at 20% B for 5 min. The flow rate was maintained at 
0.5 mL/min, the column temperature at 25 oC, and the injection volume 
was 10 µL. UV detection wavelength measured at 225 nm with a 4 nm 
bandwidth. 
5.3 Results and Discussion 
5.3.1 Enzyme Screening 
The model ADC used in this project was engineered to be sensitive 
to lysosomal proteases. It has two valine-citrulline linkers that can be 
cleaved with cathepsin B. However, cathepsin B was not 100% effective 
and it is very expensive. Therefore, we performed screening assay to 




enzymes including: cathepsin B (extracted from human liver), cathepsin B 
(extracted from bovine spleen), bromelain, pepsin, cathepsin D, trypsin 
and chymotrypsin. We determined the amount of free drug that was 
cleaved from ADC within 24 hours to evaluate the efficiency of the enzyme. 
The results are shown in Figure 5.2. The four cysteine proteases, 
including cathepsin B (human liver), cathepsin B (bovine spleen), 
cathepsin D and bromelain, can cleave off free drug from ADC. However, 
the other four enzymes, which are aspartate and serine proteases, 
showed very low efficiency of cleavage. Among the four effective cysteine 
proteases, bromelain achieved the best cleavage efficiency. Therefore, we 
chose bromelain as our enzyme instead of the originally designed 
cathepsin B. Another significant advantage of bromelain is that its cost is 













Figure 5.2 Comparison of the release of the free drug from the model 







5.3.2 Method Validation 
Figure 5.3 shows pictures of solutions of ADC treated with 
cathepsin B (Figure 5.3B) and bromelain (Figure 5.3C). The first picture 
(Figure 5.3A) shows a picture of the control group without any enzyme 
treatment. The model ADC produced a blue precipitant after being treated 
with acetonitrile and centrifuged. Figure 5.3B is the ADC deconjugated 
with cathepsin B. In this case, some free drug was cleaved and released 
into solution so the solution turned to blue and the blue color of ADC 
precipitant became lighter. However, when the ADC was treated with 
bromelain (Figure 5.3C), all of the drug was cleaved and released into the 
solution, so the antibody precipitant became white and the solution 
became dark blue. This straightforwardly proved that bromelain could 
completely cleave off free drug from ADC. 
Other quantification validations were also performed, including 
precision, limits of quantification, calibration curve, and spike recovery. 
The precision was determined with 100 μg/mL ADC. The system precision 
was evaluated by injecting the same sample five times, while the method 
precision was evaluated by performing the entire enzyme deconjugation 
and LC-UV analysis five times. The system precision %RSD and method 
precision %RSD are 0.2% and 1.4%, respectively. The spike recovery was 
determined by spiking 100 µg/mL of the free drug standard into the bare 




of with this method. The detailed results are shown in Table 5.1. This 















Figure 5.3 Pictures of the ADC samples treated with cathepsin B and 





















We studied the stability of ADC in the presence of two types of 
reagents. The first type was the conjugation reagent. During the ADC 
conjugation process, many reagents are used, for example N,N-
dimethylacetamide (DMA), N,N-dimethylformamide (DMF), dimethyl 
sulfoxide (DMSO), polyglycol (PG), hydrogen peroxide, L-methionine 
sulfoximine (MSX), DL-dithiothreitol (DTT), (L)-dehydroascorbic acid 
(DHA), N-acetyl-L-cysteine (NAC) and Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) and arginine. If the amounts of these conjugation 
reagents are not well controlled, they might still be present in the ADC 
sample after conjugation process and affect the stability of ADC. The 
second type is formulation excipients, which are mixed with ADC to form 
dosage form, for example sodium acetate, sodium phosphate, sodium 
citrate, sodium tartrate, EDTA, NaCl, lactose, sucrose, trehalose, PS 20. 
We also want to investigate if they will affect the stability of ADC. 
To perform the study, the ADC sample was first mixed with one of 
reagents of interest listed above and vortexed. The vial was stored in a 40 
oC and 75% humidity in an oven. There were three time points used: day 1, 
day 7, and another sample without incubation as day 0. Then they were 
deconjugated by bromelain and analyzed by the LC-UV method described 
in this chapter.  




illustrate the analysis of each reagent. Three different concentrations of 
MSX were studied (1, 10, 100 mM). MSX was mixed with the ADC sample 
and stored at 40 oC and at 75% humidity for 0 day, 1 day and 7 days. 
Another ADC sample was mixed with water only without any MSX to serve 
as control. On the chromatogram shown in Figure 5.4, the peak at ~ 27 
min is the free drug peak, whose peak area change is used to evaluate 
drug degradation. The model ADC was compatible with low concentrations 
(1 mM) MSX from day 0-7. However, with higher concentrations (10 and 
100 mM), the ADC is only stable within the first 24 hours and the free drug 
peak decreased and degradation peaks started to form at day 7. 
Figure 5.5 and 5.6 show a summary of all the compatibility study 
results. The color of each block on the table indicates the free drug peak 
area loss compared to control. The darker blue color means the reagents 
are less compatible with our ADC sample. The following section discusses 









Figure 5.4 Compatibility study results of MSX. LC-UV 
chromatograms are shown on the left. Quantification comparisons of free 











































































































5.4.1 Conjugation Reagents 
5.4.1.1 Organic Solvents 
PG, DMA, DMF, and DMSO are typically used to dissolve 
hydrophobic small molecules during the conjugation process. They 
improve the solubility of small molecules as well as conjugation 
efficiencies. DMA, DMF, and DMSO were diluted in deionized water to 20% 
pH adjusted to 5, 7 and 9 with HCl and NaOH. PG was diluted to 10%, 25% 
and 50% pH adjusted to 5, 7 and 9. No obvious changes in free drug were 
observed. 
5.4.1.2 H2O2 
H2O2 is used to clean the labware, so there might be trace amounts 
left in the drug sample. In these experiments, concentrations of 0.01, 0.05 
and 0.1% (v/v) of H2O2 were studied. Sine H2O2 is a strong oxidant; even 
the lowest concentration of H2O2 resulted in 80% of free drug peak loss 
within 24 hours. 
5.4.1.3 Methionine Sulfoximine 
MSX is an irreversible inhibitor of glutamine synthetase. It is 
commonly added in cell cultures to inhibit growth of unwanted bacteria and 
fungus. MSX concentrations of 1mM, 10mM and 100mM MSX were 
studied. The results show that in the presence of 1mM MSX, the free drug 
was stable for 7 days. As the MSX concentration increased, degradation 





NAC is used to clear out linker drug residue in the conjugation 
process by reacting with unreacted maleimide functional groups. The 
result showed that it was incompatible with the small molecule drug on 
ADC even with low concentrations. We analyzed the degradation with 
TOF LC-MS; the result showed that the NAC added to the cytotoxic drug 
moiety. 
5.4.1.5 Dithiothreitol and Tris(carboxyethyl)phosphinehydrochloride 
DTT and TCEP are two commonly used reductants in the antibody 
conjugation process. They are used to reduce the disulfide bond and open 
the interchain of antibody, so the linker or cytotoxic drug can be 
engineered to the antibody. In the presence of 1 mM TCEP, the small 
molecule drug was stable for seven days. Since TCEP has strong 
reducing capability at high concentrations, TCEP became incompatible 
with the model ADC at 10 mM and 100 mM. DTT also has strong reducing 
capability, the ADC was unstable under any conditions in the presences of 
DTT. 
5.4.1.6 Dehydroascorbic acid 
DHA is an oxidant. It has a function opposite to that of DTT and 
TCEP. DHA is used to reoxidize the opened interchain disulfide bond. 
Similarly to TCEP, ADC was compatible with low concentrations of DHA. 




two degradation peaks were formed. 
5.4.1.7 Arginine 
Arginine was added to improve the solubility and inhibit protein 
aggregation during the conjugation reaction. An obvious decrease in the 
free drug peak was observed; however, no obvious degradation peak 
appeared with the 225 nm UV spectrum. This might because the new 
degradation products that were produced  absorbed at another 
wavelength, . 
5.4.2 Formulation Excipients 
5.4.2.1 Buffer 
Acetate, phosphate, citrate and tartrate are the four commonly used 
buffers in the formulation of ADCs. Studies have shown that they might 
have the drug stability issues in formulation. Therefore buffers at 1, 10, 
100 mM and pH 5, 7, 9 for each sample were tested. The results showed 
higher concentrations and pH values of phosphate and citrate buffer 
caused stability issues. The reason could be that phosphate is a 
nucleophile and attacks electrophilic centers. Citrate buffers are normally 
used between pH 3.0-6.2. In this case, the instability could be due to the 
high pH conditions used where the buffer capacity is low. 
5.4.2.2 Chelating reagents 
EDTA and citrate were added to the ADC formulation as chelating 




degradation peaks were observed, this suggested EDTA under went 
degradation.  
5.4.2.3 Sugar and Other Reagents 
Lactose, sucrose and trehalose are sugars used as bulking agents 
and lyoprotectants that protect freeze-dried drug in the formulation. NaCl 
is a tonicity adjusting agent and PS 20 is a commonly used surfactant in 














Figure 5.5 Compatibility study results summary of the conjugation 















Figure 5.6 Compatibility study results summary of the formulation 









An enzymatic deconjugation method was successfully developed 
and validated for the analysis of small molecule drugs in ADCs. A 
systematic compatibility investigation of conjugation reagents and 
formulation excipients with ADC was carried out. The future ADC engineer 
researchers can refer to the compatibility study results to improve the 
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6 Conclusions and Future Directions 
6.1 CE-LIF Method Development for the Determination of 
Amino Acids in Rat Brain Microdialysates to Study 
Epileptic Seizure 
6.1.1 Conclusions 
Oxidative stress is an important secondary effect of epileptic 
seizure. Nitric oxide is one of the reactive nitrogen species in the brain.1,2 
In this project, ornithine and citrulline were chosen as stable indicators of 
nitric oxide production in rat brain during epileptic seizures. 
We first developed a capillary electrophoresis with laser induced 
fluorescence (CE-LIF) method to detect ornithine and citrulline in rat brain 
microdialysis samples. Ornithine and citrulline were derivatized with 4-
(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (DBD-F)3, and 
then they were separated by cyclodextrin assisted capillary 
electrophoresis. 2-hydroxypropy-beta-cyclodextrin and ethanol were 
added into background electrolytes to improve resolutions. The limit of 
detection (LODs) for ornithine and citrulline were 23 nM and 9 nM 
respectively. 
This method was employed in an in vivo awake rat microdialysis 
study. The microdialysis probe was implanted into rat brain hippocampus 




through the probe as convulsant to induce focal seizure.4,5 The results 
showed, after 3-MPA dosing, the concentration of citrulline increased by 
~50% and the concentration of ornithine increase by ~100%. Citrulline and 
ornithine both stayed relatively leveled for ~3 hours. This confirmed the 
NO production during epileptic seizure. 
6.1.2 Future Directions 
The DBD-F derivatization and cyclodextrin modified CE separation 
not only can be applied to ornithine and citrulline in rat brain microdialysis 
samples, but also for the determination of other amino acids in 
microdialysis samples. 
The change in ornithine and citrulline concentration as a function of 
time can be compared with other studies in the future to get a better 
picture of the role of oxidative stress in epileptic seizure. It also can be 
correlated with other biomarkers to determine the oxidative damage due to 
oxidative stress in epileptic seizure. Furthermore, it also can be correlated 
with the study of how antioxidants modulate oxidative damage. 
6.2 LC-MS Method Development of Eicosanoids in Rat Colon 
Microdialysate to Study Inflammatory Bowel Disease 
6.2.1 Conclusions 
Cyclooxygenase (COX) and lipoxygenase (LOX) are two enzymatic 
pathways in inflammatory bowel disease (IBD). We chose 13 eicosanoids 




enzymatic mechanisms of IBD.6,7 In this project, we focused on the 
development of a LC-MS/MS method to study the biomarkers in rat colon 
microdialysate. 
We first successfully developed an LC-MS/MS method to separate 
and detect the 13 eicosanoids. The separation was obtained on a reverse 
phase LC column. Gradient elution with A: water and 60 mM acetic acid B: 
acetonitrile with 60 mM acetic acid was used to separate 13 eicosanoids. 
MS conditions were optimized to achieve the best LODs. 
2-Hydroxypropy-beta-cyclodextrin was added in the microdialysis 
perfusate to improve the recovery of hydrophobic analytes from 5–30% to 
40–85%. The cyclodextrin also managed to improve the solubility of 
hydrophobic analytes, which prevented the analytes from precipitating out 
of the solution or attaching to the vial walls. The LODs were further 
improved to ~2 nM. 
6.2.2 Future Directions 
In the future, this LC-MS method will be used in the analysis of in 
vivo rat colon microdialysis study of IBD. 2,4,6-trinitrobenzene sulfonic 
acid (TNBS) will be perfused into rat colon to induce IBD8, and the 
concentration change of the eicosanoids will be monitored to investigate 
the enzymatic mechanism of IBD. Furthermore, rats will also be dosed 
with several IBD medications on the market, and the enzyme activities can 




6.3 Enzymatic Deconjugation to Study Stability of Antibody 
Drug Conjugates 
Antibody drug conjugates (ADCs) are a new class of anticancer 
drugs that improve the cytotoxic drug’s specificity while maintaining its 
potency.9 In this project, we chose bromelain as an enzyme to fully cleave 
off the small molecule cytotoxic drug from the ADC prior to the analysis. 
With this enzymatic deconjugation method, we were able to directly 
investigate the degradation of small molecule toxins with the LC-UV 
method. One application of this method is to study the stability of the 
model ADC under different conditions. There are two types of conditions 
studied: in the presence of left over conjugation reagents and with 
formulation excipients. Two tables were generated to summarize the ADC 
stability under different conditions. ADC engineer researchers can refer to 
the compatibility study results to improve the stability of ADC formulations 
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